Login
Create Account
POSTER SESSION - Tuesday
Tuesday, 09 June 2026 (10:30 - 20:00)
Main Category
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
BIOMARKERS IN TISSUE AND BLOOD
CANCER CELL BIOLOGY
CANCER GENOMICS
CARCINOGENESIS
DRUG RESISTANCE
EPIGENETICS
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
IMMUNOTHERAPY
MOLECULAR AND GENETIC EPIDEMIOLOGY
PREVENTION AND EARLY DETECTION
RADIOBIOLOGY / RADIATION ONCOLOGY
SIGNALING PATHWAYS
TRANSLATIONAL RESEARCH
TUMOUR BIOLOGY
TUMOUR EVOLUTION AND HETEROGENEITY
TUMOUR IMMUNOLOGY
Session
Presenter & Country
Abstract No
Poster No
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
Utilization of Multiple Consensus Housekeeping Genes for the Discovery of Pan-cancer Biomarker Genes Using GTEx and TCGA Datasets
Wen-chang Lin
Taiwan
EACR26-0094
P-001
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
Stemness-Associated Differentiation System in High-Grade Serous Ovarian Carcinoma Revealed by Single-Cell Transcriptomics
Uygar Yucekaya
Turkey
EACR26-0116
P-002
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
Tumor Immunogenicity Unlocked: Multi-omics Models Predict Immunotherapy Response and Survival
Axel Gschwind
Germany
EACR26-0212
P-003
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
Estimation of chemotherapy benefit in breast cancer patients using machine learning
Ankita Murmu
Hungary
EACR26-0654
P-004
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
Single-cell transcriptomics reveals linear resistance trajectories and MET as a potential early target in BRAF-mutated melanoma
Alba de la Puente
Spain
EACR26-0688
P-005
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
Beyond BMI: AI-Based CT body composition reveals a metabolic stress phenotype in colorectal cancer patients associated with postoperative complications
Bettina K. Budai
Germany
EACR26-0696
P-006
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
Validation of Cell Surface Proteomics for Drug Target Identification and Biomarker Discovery in Triple-Negative Breast Cancer
Paula Carrillo Rodríguez
Spain
EACR26-0840
P-007
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
Epigenetic state-control and immune visibility show divergent hallmark footprints and prognostic effects in breast cancer
Otilia Menyhart
Hungary
EACR26-0912
P-009
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
Integrative proteogenomic and computational analysis of a Helicobacter pylori ecospecies associated with high gastric cancer risk
Homen Phukan
Sweden
EACR26-1014
P-010
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
Inferring Co-Regulated Programs Across Cell Types in the Brain Tumor Microenvironment
Caroline Wandinger
Switzerland
EACR26-1042
P-011
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
Metabolomics data quality in cancer epidemiology: a metabolomics approach to lipid reprogramming by Mediterranean diet in women with metabolic syndrome
Giulia Guerra
Italy
EACR26-1048
P-012
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
A Long-Read RNA Sequencing Pipeline for Transcript-Origin–Resolved Tumor Antigen Discovery
Lan-Yu Lin
Taiwan
EACR26-1054
P-013
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
TNMplot: an upgraded transcriptomic database for cross-stage biomarker and drug target analysis
Otilia Menyhart
Hungary
EACR26-1158
P-014
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
Spatially resolved profiling of myeloid activation refines methylation-based risk stratification in meningioma
Domenico Calafato
Germany
EACR26-1174
P-015
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
Immune features are associated with response to Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer
Amen Shamim
United Kingdom
EACR26-1184
P-016
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
Intersection of GALR2 expression with gene signatures for hypoxia and macrophage phenotype in HNSCC: A Multi-Omic Study
Ianny Brum Reis
Brazil
EACR26-1248
P-017
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
Mapping drug targets at single-cell resolution in kidney cancer
Zsófia Dobolyi
Hungary
EACR26-1370
P-019
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
Long-read sequencing reveals genetic and epigenetic alterations in pancreatic neuroendocrine tumors
Joe Ibrahim
Belgium
EACR26-1436
P-020
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
BRCA Mutation Status and HRD-Like Signals Associate with Distinct Tumor Microenvironment subtypes in Male Breast Cancer
Giovanni Guglielmelli
Italy
EACR26-1442
P-021
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
LAMA2 downregulation via the circRNA–hsa-miR-224 axis facilitates immune evasion and metastasis in non-small cell lung cancer
Jihye Yang
South Korea
EACR26-1472
P-022
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
Spatial organization and therapeutic vulnerabilities of drug-tolerant persister programs in HER2-positive breast cancer
Thanh Hoa Vo
Ireland
EACR26-1474
P-023
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
DECIPHERING THE CANONICAL AND NONCANONICAL PROTEOME IN OVARIAN CANCER UNDER HMGB1/2 MODULATION
Inés Bao-Camacho
Spain
EACR26-1476
P-024
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
Optimizing Speed and Resolution in Spatial Phenotyping: An Analysis of Image Acquisition Modes
Luise Rupp
United States
EACR26-1522
P-025
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
Potential mechanism of action of anticancer peptides from reptiles predicted by computational methods
Claudia Machicado
Peru
EACR26-1690
P-026
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
KRASense: Computational protein design of KRAS-responsive intracellular effectors for selective tumour cell killing
Metoboroghene Mowoe
Sweden
EACR26-1790
P-029
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
Cellular Heterogeneity and Tumor Microenvironment Dynamics in Adult Gliomas
Lívia Fonseca
Brazil
EACR26-1818
P-030
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
Artificial Intelligence for Early Detection of Cancer Therapy-Related Cardiotoxicity and Its Impact on Surgical Oncology Outcomes
Taanish Unhale
United Kingdom
EACR26-1822
P-031
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
NucAE: Autoencoder-based denoising of cell-free DNA nucleosome footprints for tumor profiling
Zsolt Balázs
Switzerland
EACR26-1860
P-032
BIOMARKERS IN TISSUE AND BLOOD
Integrative Analysis of Metabolic and lncRNA Remodeling During Breast Cancer Progression
Subash Gupta
India
EACR26-0060
P-035
BIOMARKERS IN TISSUE AND BLOOD
The Clinical value of PPP2R4 and its protein complex in colorectal cancer
Xingzhi Jiang
United Kingdom
EACR26-0070
P-036
BIOMARKERS IN TISSUE AND BLOOD
Contactin-1 expression in colorectal cancer predicts poor outcomes in patients with lymph node involvement and advanced Dukes stage
Amber X. Li
United Kingdom
EACR26-0072
P-037
BIOMARKERS IN TISSUE AND BLOOD
Platelet transcriptomics as a source of response biomarkers in breast cancer: a pilot exploratory study
Izaskun Urdanibia
Spain
EACR26-0106
P-038
BIOMARKERS IN TISSUE AND BLOOD
Circulating tumor DNA–derived PSA and PSMA identify patients at high risk of progression in metastatic hormone-sensitive prostate cancer
Jae-Seung Chung
South Korea
EACR26-0166
P-039
BIOMARKERS IN TISSUE AND BLOOD
Circulating inflammatory markers in survival prediction of endometrial cancer.
LAURA VALIÑA AMADO
Spain
EACR26-0172
P-040
BIOMARKERS IN TISSUE AND BLOOD
Longitudinal plasma protein trajectories stratify survival and reveal chemotherapy resistance in esophageal adenocarcinoma
Vanessa Detlefsen
Germany
EACR26-0186
P-041
BIOMARKERS IN TISSUE AND BLOOD
Wnt/β-catenin driven EMT protein profiles improve prognostic stratification and reveal therapeutic targets in colorectal cancer.
Amna Matly
United Kingdom
EACR26-0252
P-042
BIOMARKERS IN TISSUE AND BLOOD
Progressive Changes in Circulating Cell-Free DNA in Response to Environmental Carcinogen Exposure: A Longitudinal Study in Murine Lung Cancer Models
Saumya Patel
India
EACR26-0270
P-043
BIOMARKERS IN TISSUE AND BLOOD
Study of the response to cytotoxic chemotherapy and targeted therapy in a cohort of patients with metastatic colorectal cancer using artificial intelligence-based networks
Marco Peluso
Italy
EACR26-0316
P-044
BIOMARKERS IN TISSUE AND BLOOD
ctDNA monitoring in metastatic breast cancer complements functional mass cytometric detection of homologous recombination proficiency in circulating tumor cells to predict chemoresistance
Sara Greco
Germany
EACR26-0370
P-045
BIOMARKERS IN TISSUE AND BLOOD
Circulating endothelial-like cells as prognostic factors of glioblastoma relapse
András Rubics
Hungary
EACR26-0388
P-046
BIOMARKERS IN TISSUE AND BLOOD
Decision Tree-derived micro RNA Signatures of Pleural Fluid for the Diagnosis of Malignant Pleural Effusion secondary to Lung Squamous Cell Carcinoma
Maria Alba Sorolla
Spain
EACR26-0400
P-047
BIOMARKERS IN TISSUE AND BLOOD
Spatial Characterization of Tertiary Lymphoid Structures in Melanoma and Their Association with Recurrence
Benedetta Apollonio
Italy
EACR26-0462
P-048
BIOMARKERS IN TISSUE AND BLOOD
Metrologically traceable quantification of NRAS p.Q61R by digital PCR
Jessica Petiti
Italy
EACR26-0466
P-049
BIOMARKERS IN TISSUE AND BLOOD
DNA Methylation Biomarker for Non-Muscle Invasive Bladder Cancer Prognostication
Nuha Al-Jabri
Oman
EACR26-0504
P-050
BIOMARKERS IN TISSUE AND BLOOD
Liquid Biopsy–Driven Genomic Profiling Enhances Tissue‑of‑Origin Prediction and Therapeutic Target Identification in Unfavorable CUP
Jana Löptien
Germany
EACR26-0574
P-051
BIOMARKERS IN TISSUE AND BLOOD
Spatial and Single-Cell Profiling Identify Tfh Niches and CD8⁺ Exhaustion as Drivers of Glofitamab Resistance in B-NHL
Paul Marcoux
France
EACR26-0682
P-053
BIOMARKERS IN TISSUE AND BLOOD
DRIM–SIK signaling defines a novel molecular axis with prognostic significance in breast cancer
Kim Chu
United Kingdom
EACR26-0738
P-054
BIOMARKERS IN TISSUE AND BLOOD
Detection of HPV ctDNA before and after ChemoradioTherapy in women with cervical cancer
SUJATA PATHAK
India
EACR26-0810
P-055
BIOMARKERS IN TISSUE AND BLOOD
Multimodal analysis of cell-free DNA in pediatric and adult patients with fusion-driven sarcomas
Panna Lajer
Germany
EACR26-0868
P-056
BIOMARKERS IN TISSUE AND BLOOD
Differential KEAP1/NRF2 signaling widens therapeutic window of TXNRD1 inhibitors in SCLC therapy
Hana Nůsková
Germany
EACR26-0892
P-057
BIOMARKERS IN TISSUE AND BLOOD
Analytical Validation of an NGS Panel for Actionable cfDNA Alterations in Non-Small Cell Lung Cancer
Roberto Serna-Blasco
Spain
EACR26-0926
P-058
BIOMARKERS IN TISSUE AND BLOOD
Chemokines and their Receptors as Prognostic Biomarkers for Immune Checkpoint Therapy in Solid Tumours
Gergő Holló
Hungary
EACR26-0944
P-059
BIOMARKERS IN TISSUE AND BLOOD
Bioinformatics-Guided Selection of CCT2, MYC, and PPP2R2C in Blood and Stool for Non-Invasive Early Detection of Colorectal Cancer and Development of a Dual-Compartment RNA-Based Diagnostic Kit
Ebrar TUTAR TORUN
Turkey
EACR26-0974
P-060
BIOMARKERS IN TISSUE AND BLOOD
Spatial Transcriptomic Profiling of the Tumor Stroma Identifies Prognostic Signatures in Stage I Lung Adenocarcinoma and Squamous Cell Carcinoma
Jozafina Haj-Shomaly
United Kingdom
EACR26-1108
P-061
BIOMARKERS IN TISSUE AND BLOOD
Clinical Proteome Profiling Reveals ADC-Specific Response Mechanisms in HER2-Positive Breast Cancer
Luca Finn Gaessler
Sweden
EACR26-1166
P-062
BIOMARKERS IN TISSUE AND BLOOD
Prognostic Significance and Functional Role of IL-17RC in Oral Squamous Cell Carcinoma
Bruno Cesar da Costa
Brazil
EACR26-1176
P-063
BIOMARKERS IN TISSUE AND BLOOD
NANS Defines an Adhesion-Dependent Immunoregulatory Macrophage Phenotype Associated with Poor Survival in Glioblastoma
Arnold Etame
United States
EACR26-1180
P-064
BIOMARKERS IN TISSUE AND BLOOD
A Plasma Derived Hypoxia Signature Predicts Benefit from Hypoxia-Modifying Therapy and Reveals Dynamic Humoral Immune Modulation in Bladder Cancer
Conrado Guerrero Quiles
United Kingdom
EACR26-1204
P-065
BIOMARKERS IN TISSUE AND BLOOD
Functional and clinical impact of mitochondrial DNA mutations in ovarian and colorectal cancer
Chiara Trento
Italy
EACR26-1206
P-066
BIOMARKERS IN TISSUE AND BLOOD
Defining immune markers and transcriptome changes in benign breast disease to predict risk of node-positive breast cancer development
Matilde Rossi
United States
EACR26-1214
P-067
BIOMARKERS IN TISSUE AND BLOOD
Circulating tumor cells capture tumor heterogeneity and enable preclinical modeling of neuroendocrine lung tumors
Francesca Bersani
Italy
EACR26-1220
P-068
BIOMARKERS IN TISSUE AND BLOOD
KLK3 rs17632542 SNP alters PSA activity and PSA fractions, biasing detection and linking to lethal disease
Rupert Ecker
Australia
EACR26-1310
P-070
BIOMARKERS IN TISSUE AND BLOOD
BMI1: A Novel Prognostic Biomarker in High-Grade Serous Carcinoma
Lilla Csellar
Finland
EACR26-1312
P-071
BIOMARKERS IN TISSUE AND BLOOD
Proteogenomic Characterisation of Triple-Negative Breast Cancer Uncovers Patient-Specific Protein Network Programs and Therapeutic Vulnerabilities
Henrik Johansson
Sweden
EACR26-1366
P-072
BIOMARKERS IN TISSUE AND BLOOD
PROFILUX: Saliva- and blood-based lung cancer detection based on tumor auto-antibody profiling
Andreas Weinhaeusel
Austria
EACR26-1372
P-073
BIOMARKERS IN TISSUE AND BLOOD
Ensuring antibody reliability in cancer research: TROP2 as an example of Abcam’s enhanced validation approach
Silvia Sbacchi
United Kingdom
EACR26-1430
P-074
BIOMARKERS IN TISSUE AND BLOOD
INTERSTITIAL FLUID OBTAINED FROM ADIPOSE TISSUE PROXIMAL TO THE TUMOR MAY REPRESENT A NEW SOURCE FOR BIOMARKERS IN BREAST CANCER
Lorenza Zinna
Italy
EACR26-1432
P-075
BIOMARKERS IN TISSUE AND BLOOD
Prediction of Growth in Vestibular Schwannomas: Nano-Omics Enabled Discovery of Circulating Prognostic Biomarkers
Olivia Iwanowytsch
United Kingdom
EACR26-1484
P-076
BIOMARKERS IN TISSUE AND BLOOD
Predictive Blood Biomarkers for the Development and Progression of Chemotherapy-Induced Peripheral Neuropathy: A Systematic Review
Pascal Paco Farina
Ireland
EACR26-1504
P-077
BIOMARKERS IN TISSUE AND BLOOD
Ribosome Quality Control Pathway Activation as a Tool for Cancer Diagnostics
Cinthia Amaya Ramirez
Germany
EACR26-1530
P-079
BIOMARKERS IN TISSUE AND BLOOD
EGFR and SQSTM1/p62 expression as predictors of chloroquine sensitivity in glioblastoma
Milou Schattefor
Netherlands
EACR26-1638
P-080
BIOMARKERS IN TISSUE AND BLOOD
Integrating Circulating Tumour DNA Profiling with Clinical Data in Small Cell Lung Cancer
Aslı Kutlu
Turkey
EACR26-1650
P-081
BIOMARKERS IN TISSUE AND BLOOD
CDK4/6 inhibition reshapes immune landscapes and uncovers TIM3 as a clinically relevant biomarker
Sara Cabrero-de las Heras
Spain
EACR26-1664
P-082
BIOMARKERS IN TISSUE AND BLOOD
Not All Clones Reach the Blood: Investigating the Representativeness of Liquid Biopsy
Davide Ceresa
Italy
EACR26-1666
P-083
BIOMARKERS IN TISSUE AND BLOOD
Reactivation of the meiotic gene C14orf39 drives malignant progression and increases relapse risk in non-small cell lung cancer
Yi Liu
Spain
EACR26-1704
P-084
BIOMARKERS IN TISSUE AND BLOOD
Multimodal liquid biopsy analysis in patients with sporadic Medullary Thyroid Carcinoma (spMTC)
Elina Lagopodi
Greece
EACR26-1714
P-085
BIOMARKERS IN TISSUE AND BLOOD
High-Throughput Compatible Whole Blood Functional Assays for Accelerated Characterization of Therapeutic Antibodies and Biosimilars
Ines AIT BELKACEM
France
EACR26-1734
P-086
BIOMARKERS IN TISSUE AND BLOOD
Longitudinal DNA methylation analysis in plasma cell-free DNA of NSCLC patients monitored during treatment with ICIs
Aliki Ntzifa
Greece
EACR26-1742
P-087
BIOMARKERS IN TISSUE AND BLOOD
A unified workflow for spatial detection of protein–protein proximity, RNA signatures, and protein phenotypes in tumors
Arec Manoukian
Switzerland
EACR26-1746
P-088
BIOMARKERS IN TISSUE AND BLOOD
The prognostic role of soluble HVEM in non-small cell lung cancer treated with immune checkpoint inhibitors combined or not with platinum-based chemotherapy
Martina Bottone
Italy
EACR26-1782
P-089
BIOMARKERS IN TISSUE AND BLOOD
Analytical performance of a highly sensitive, distributable whole-genome sequencing (WGS) assay for molecular residual disease (MRD) detection research
Yuan Ding
United States
EACR26-1808
P-090
BIOMARKERS IN TISSUE AND BLOOD
Serum trace element dysregulation as a potential non-invasive biomarker signature in Glioblastoma
Giorgio Avilia
Italy
EACR26-1856
P-092
CANCER CELL BIOLOGY
Centaureidin Induces Apoptosis in Human Oral Cancer Cells via Caspase Activation and the Mitochondrial Pathway
Chia-Chieh LIN
Taiwan
EACR26-0026
P-095
CANCER CELL BIOLOGY
Pancreatic Cancer Stem Cells Co-Expressing SOX2, OCT4, and TERThigh Represent an Aggressive Subpopulation
Erika Curiel Gomez
Mexico
EACR26-0096
P-097
CANCER CELL BIOLOGY
Tumor-Suppressive Functions of piR-36712 in Ovarian Cancer Stem Cells
Sude OZDEMIR
Turkey
EACR26-0110
P-098
CANCER CELL BIOLOGY
LRP-1 promotes tumor progression of triple negative breast cancer through the ECM remodeling
Abdelilah Aziz
France
EACR26-0120
P-099
CANCER CELL BIOLOGY
CDK1-mediated phosphorylation of EPLIN is crucial for mitotic spindle positioning
Hong-Chen Chen
Taiwan
EACR26-0138
P-101
CANCER CELL BIOLOGY
Targeting ERO1α Triggers Tumor Immunosurveillance in Triple-Negative Breast Cancer
Ester Zito
Italy
EACR26-0144
P-102
CANCER CELL BIOLOGY
Synergistic Induction of Apoptosis and Autophagy by 10-Hydroxy-2-Decenoic Acid and Cisplatin in Human Cervical Cancer Cells
Chih-Chung Wu
Taiwan
EACR26-0224
P-105
CANCER CELL BIOLOGY
Pharmacological Targeting of the IL20RA Signaling Axis: A Novel Therapeutic Strategy for Triple-Negative Breast Cancer
Francesca De Amicis
Italy
EACR26-0248
P-107
CANCER CELL BIOLOGY
A rationally designed multi-targeted natural compound cocktail synergises with temozolomide to overcome therapy resistance in glioblastoma by inducing G2–M cell cycle arrest and suppressing MGMT expression
Ahmed Musah-Eroje
United Kingdom
EACR26-0250
P-108
CANCER CELL BIOLOGY
Differential Modulation of VEGF Expression and Apoptotic Signaling by Therapeutic Agents in PANC-1 Pancreatic Carcinoma Cells
Duygu Sari Ak
Turkey
EACR26-0274
P-109
CANCER CELL BIOLOGY
Therapeutic targeting of ROCK reactivates Hippo Signalling and reverses EMT through impeding nuclear translocation of TAZ in lung cancer cells
Basab Ghosh
India
EACR26-0286
P-110
CANCER CELL BIOLOGY
The lipogenic enzyme SCD1 is regulated by microbiota and can be therapeutically exploited in CRC
Florian Jokisch
Germany
EACR26-0320
P-111
CANCER CELL BIOLOGY
Targeting chromosomal instability in childhood B-cell acute lymphoblastic leukemia with aneuploidies: unveiling molecular mechanisms for precision therapy
Cristina Calvo
Spain
EACR26-0332
P-112
CANCER CELL BIOLOGY
Extracellular vesicles released by mast cells promote breast cancer stem-like features
Daniele Lecis
Italy
EACR26-0336
P-113
CANCER CELL BIOLOGY
Inhibition of p38 mitogen activated protein kinase enhances paclitaxel-induced microtubule stabilization and cytotoxicity in an MDA-MB-231 derived resistant cell clone
Ling-Huei Yih
Taiwan
EACR26-0344
P-114
CANCER CELL BIOLOGY
Amiodarone exerts anti-cancer effects in thyroid cancer through cell cycle arrest, mitochondrial dysfunction, and activation of autophagy and apoptosis
Taewoong You
South Korea
EACR26-0356
P-115
CANCER CELL BIOLOGY
PSIP1 promotes metastatic progression through p38 MAPK–associated transcriptional regulation in oral squamous cell carcinoma
WEI-EN YANG
Taiwan
EACR26-0358
P-116
CANCER CELL BIOLOGY
Therapeutic Targeting of Mutant p53–Driven UPR Addiction Overcomes ER Stress Resistance in Metastatic Prostate Cancer
Evangelos Pavlakis
Germany
EACR26-0382
P-117
CANCER CELL BIOLOGY
Efficient FOXC1 gene editing reveals a therapeutic vulnerability in triple-negative breast cancer
Anabel Sorolla
Spain
EACR26-0390
P-118
CANCER CELL BIOLOGY
Epigenetic and transcriptional regulation of TRPM4 by EWS::FLI1 : Role in the development of Ewing sarcoma
Edith Loisy
France
EACR26-0428
P-119
CANCER CELL BIOLOGY
ROS-Dependent Additive Inhibition of Glioblastoma Cell Proliferation by Repurposed metformin and pantoprazole
Kristina Janjetović
Serbia
EACR26-0440
P-120
CANCER CELL BIOLOGY
E2F1 and E2F2 regulate a transition from proliferation to survival in colorectal cancer cells
Ainhoa Eriz
Spain
EACR26-0472
P-121
CANCER CELL BIOLOGY
ALDH1A3-Dependent miRNA and Extracellular Vesicle Networks Drive Metastatic Behaviour in Triple-Negative Breast Cancer
Raj Pranap Arun
Canada
EACR26-0474
P-122
CANCER CELL BIOLOGY
Endo180 and Basement Membrane Stiffness induce OXPHOS in Aging Prostate
Mercedes Rodríguez-Teja
Uruguay
EACR26-0478
P-123
CANCER CELL BIOLOGY
Targeting oncogenic DUSP6 in HER2-inhibitor resistant breast cancer brain metastasis
Shruti Bhardiya
Finland
EACR26-0516
P-124
CANCER CELL BIOLOGY
Regorafenib induces distinct metabolic and survival responses in well-established and patient-derived osteosarcoma models
Klaudia Marcinkowska
Poland
EACR26-0518
P-125
CANCER CELL BIOLOGY
A Novel CDK9 inhibitor, GT-02897, selectively induces cytotoxic effects and exhibits preclinical synergistic activity in Myeloma
Osman Aksoy
Austria
EACR26-0530
P-126
CANCER CELL BIOLOGY
Cell autonomous VEGF-C Promotes Ferroptosis Resistance through Glutamine-Dependent Redox Reprogramming in Pancreatic Cancer
YU-JING TAI
Taiwan
EACR26-0570
P-128
CANCER CELL BIOLOGY
In search of useful cell models for studying tumor plasticity: comparative characterization of two esophageal cancer stem-like cell lines
Katarzyna Augoff
Poland
EACR26-0582
P-129
CANCER CELL BIOLOGY
OXPHOS-selective ATP suppression without glycolytic compensation underlies BAM15-regorafenib interactions in canine D17 osteosarcoma cells
Agnieszka Weronika Dolnicka
Poland
EACR26-0618
P-130
CANCER CELL BIOLOGY
FABP5 as a metabolic–inflammatory hub controlling lipid uptake, mitochondrial remodeling and NF-κB signaling in cancer
Giuseppe Fiume
Italy
EACR26-0622
P-131
CANCER CELL BIOLOGY
Treatment of colorectal cancer cells co-cultured with cancer-associated fibroblasts in a 3D FN-silk network in vitro
Veroniaina Hanitrarimalala
Sweden
EACR26-0646
P-133
CANCER CELL BIOLOGY
What is wrong in the deletion of chromosome region 5q in myelodysplastic neoplasm? Identification of a novel actor of MDS with del(5q) pathogenesis and sensitivity to lenalidomide.
Eloïse Le Hir-Reynaud
France
EACR26-0658
P-134
CANCER CELL BIOLOGY
NGFR-driven lipid metabolic reprogramming in CR-CSCs: implications for chemoresistance in colon cancer
Noemi Di Miceli
Italy
EACR26-0662
P-135
CANCER CELL BIOLOGY
Exploring metabolically-induced amino acid substitutions in cancer
Rossella Del Pizzo
Germany
EACR26-0744
P-137
CANCER CELL BIOLOGY
P62 loss promote the proliferation of ovarian cancer cells by regulation RELB pathway
Li Liu
China
EACR26-0746
P-138
CANCER CELL BIOLOGY
NPM1 Serine 125 Phosphorylation Mediates PI3K–p110α Driven Breast Cancer Proliferation
Ozlem Aybuke Isik Bozbay
Turkey
EACR26-0766
P-139
CANCER CELL BIOLOGY
Single-cell transcriptomics reveals heterogeneity of human glioblastoma stem-like cells and identifies a transitional state along the proneural–mesenchymal axis
Eunha Lim
South Korea
EACR26-0794
P-140
CANCER CELL BIOLOGY
A-MYB & B-MYB: master regulators of cell cycle genes and proliferation
Robin Kohler
Germany
EACR26-0828
P-141
CANCER CELL BIOLOGY
Triple-Negative Breast Cancer–Derived Extracellular Vesicles Compromise the Blood–Brain Barrier Through miR-146a-5p and TGF-β1–Driven Suppression of Endothelial Paqr5
Csilla Fazakas
Hungary
EACR26-0852
P-142
CANCER CELL BIOLOGY
The role of CARD14 in maintaining hepatocellular carcinoma stemness plasticity
Yalu Cui
Hong Kong, China
EACR26-0856
P-143
CANCER CELL BIOLOGY
Unmasking the cellular drivers of PanIN progression in pancreatic cancer
Beatriz Salvador-Barbero
United Kingdom
EACR26-0864
P-144
CANCER CELL BIOLOGY
PCDH20 functions as a putative tumor suppressor regulating EMT dynamics in melanoma
Esra Katkat
Turkey
EACR26-0872
P-145
CANCER CELL BIOLOGY
The role of BCR stereotypy and NOTCH1 mutations in regulating adhesion and chemotaxis in chronic lymphocytic leukemia
Nahal Nabelsi
Italy
EACR26-0878
P-146
CANCER CELL BIOLOGY
In Vitro Generation and Characterization of Drug-Tolerant Persister Cells in BRAF V600–Mutant Melanoma
Justyna Kutkowska
Poland
EACR26-0888
P-147
CANCER CELL BIOLOGY
Targeting signaling pathways triggered by Neutrophil Extracellular Traps (NETs) to induce epithelial-mesenchymal transition in non-small cell lung cancer cells.
Paola Maria Helena Esposito
Italy
EACR26-0902
P-148
CANCER CELL BIOLOGY
Cancer cells transfer invasive properties through microRNAs contained in collagen-tracks
frederic SALTEL
France
EACR26-0906
P-149
CANCER CELL BIOLOGY
Charting the multi-omic landscape of MYCN-amplified neuroblastoma reveals distinct metabolic and epigenetic changes
Andrew Roe
Ireland
EACR26-0922
P-150
CANCER CELL BIOLOGY
Anticancer activities of novel hydroxybenzoic acid derivatives in established and surgically-relevant patient-derived glioblastoma models
Sylvester Omoruyi
South Africa
EACR26-0936
P-151
CANCER CELL BIOLOGY
Targeting Complex I specifically inhibits PDAC metabolic plasticity and metastasis
Julia Zummack
Germany
EACR26-0940
P-152
CANCER CELL BIOLOGY
A senolytic ADC drives synthetic lethality and immune surveillance for senescent cancer cell destruction
Liqin Wang
China
EACR26-0950
P-153
CANCER CELL BIOLOGY
Targeting redox-driven metabolic vulnerabilities in non-V600 BRAF mutated lung adenocarcinoma
Laurine Dupriez
Belgium
EACR26-1058
P-156
CANCER CELL BIOLOGY
Deciphering the role of metabolic exchanges between tumor cells and neurons during glioblastoma development
Mathis Pinglaut
France
EACR26-1066
P-157
CANCER CELL BIOLOGY
Aberrant CRIM1 expression suppress tumorigenesis and stemness through divergent molecular pathways in HNSCC tumors
Asunción Espinosa-Sánchez
Spain
EACR26-1076
P-158
CANCER CELL BIOLOGY
Postbiotic Modulation of UV-Induced Microenvironmental Stress in a Melanoma–Skin Transwell Model
Cagla Ozdenizer
Turkey
EACR26-1086
P-159
CANCER CELL BIOLOGY
Exploring Metabolic Shielding Requirements through Cationic Molecules
Belén Martínez La Osa
Spain
EACR26-1106
P-160
CANCER CELL BIOLOGY
Differential role of ATG7 isoforms in liver cancer development
Paula Fernández-Palanca
United Kingdom
EACR26-1118
P-161
CANCER CELL BIOLOGY
FUNCTIONAL CHARACTERIZATION OF RHOA MUTATIONS IN MYC-DRIVEN B CELL LYMPHOMAGESIS
Ana Rodriguez-Fdez
Spain
EACR26-1120
P-162
CANCER CELL BIOLOGY
Reduction of HOOK2 endangers tumorigenic and stemness properties in ovarian cancer by increasing endoplasmic reticulum stress
Julia Rodrigo-Muñoz
Spain
EACR26-1138
P-164
CANCER CELL BIOLOGY
Mitochondrial YME1L regulates brain tumour initiating cell fate
Claudia Barros
United Kingdom
EACR26-1162
P-165
CANCER CELL BIOLOGY
Lipid droplet catabolism in Glioblastoma
Cloé Tessier
France
EACR26-1164
P-166
CANCER CELL BIOLOGY
Differential effects of cholesterol and testosterone supplementation on endometrioid adenocarcinoma cells
Osman Patel
United States
EACR26-1170
P-167
CANCER CELL BIOLOGY
CDK12 rewires one-carbon metabolism through mTORC1 signaling in breast cancer
Maria Grazia Filippone
Italy
EACR26-1182
P-168
CANCER CELL BIOLOGY
Profilin 1 loss drives whole-genome doubling through mitotic bypass and endoreplication in p53-proficient cells
Federica Scotto di Carlo
Italy
EACR26-1212
P-170
CANCER CELL BIOLOGY
Comparative transcriptomic analysis identifies KIF23 as a potential biomarker for cholangiocarcinoma.
Minseo Kim
South Korea
EACR26-1258
P-171
CANCER CELL BIOLOGY
Berberine Suppresses the Liver Metastasis of Colorectal Cancer by Modulating the TGF- β Signaling and Epithelial-mesenchymal Transition in an Orthotopic Cecal Transplantation of Mouse Model
Min-Young Chae
South Korea
EACR26-1278
P-173
CANCER CELL BIOLOGY
Subtype-dependent adaptive plasticity following chemotherapy in triple-negative breast cancer
Sira Ausellé-Bosch
Spain
EACR26-1348
P-178
CANCER CELL BIOLOGY
CXCR4-Targeted Peptide Induces Non-Apoptotic Cell Death in Leukemia and Breast Cancer Cells Associated with RNA-Dependent Biomolecular Condensation
Akihiko Kuniyasu
Japan
EACR26-1352
P-179
CANCER CELL BIOLOGY
Characterization of tumor heterogeneity and tetraspanin expression patterns in prostate cancer samples
Paula Hoffmanová
Czech Republic
EACR26-1380
P-180
CANCER CELL BIOLOGY
Antimetastatic effects of MRTX1133 KRAS G12D specific inhibitor in pancreatic ductal adenocarcinoma
Krisztina Szigeti
Hungary
EACR26-1426
P-181
CANCER CELL BIOLOGY
Hedgehog reactivation primes foregut keratinocytes for GATA4-induced metaplasia and tumorigenesis in vivo
Alizee Vercauteren Drubbel
Belgium
EACR26-1462
P-182
CANCER CELL BIOLOGY
Desmoglein-2 depletion drives phenotypic plasticity and remodels the surface marker landscape in breast cancer cells
Jaroslava Šafářová
Czech Republic
EACR26-1464
P-183
CANCER CELL BIOLOGY
Integrated Metabolomic–Transcriptomic Profiling Reveals Correlations Between Key Metabolic Biomarkers and Gene Expression in Doxorubicin-Resistant and -Sensitive H69 Cells
Ala Alhusban
Jordan
EACR26-1468
P-184
CANCER CELL BIOLOGY
Morphological, Functional and Single-Cell Transcriptomic Analysis Reveals a Myogenic Migratory Program in Osteosarcoma: A Longitudinal Single-Patient Study
Inga Urlic
Croatia
EACR26-1500
P-185
CANCER CELL BIOLOGY
SLC1A4-Mediated Cysteine Crosstalk Between Triple-Negative Breast Cancer and Skeletal Muscle Drives Tumor Proliferation in Cancer Cachexia
Hayeon Kim
South Korea
EACR26-1556
P-187
CANCER CELL BIOLOGY
The lactate sensing receptor HCAR1, a key player in tumor growth and metastasis, in triple-negative breast cancer model MDA-MB-231
Sofie Liljewall
Denmark
EACR26-1586
P-189
CANCER CELL BIOLOGY
From metastasis suppression to metabolic vulnerability: RKIP rewires mitochondrial metabolism in triple-negative breast cancer
Joana Pinheiro
Portugal
EACR26-1612
P-190
CANCER CELL BIOLOGY
Modelling the earliest events in lung squamous carcinogenesis using primary human bronchial epithelial cells – disruption of tumour suppressor genes, clonal competition and expansion
Alice Chernaik
United Kingdom
EACR26-1618
P-191
CANCER CELL BIOLOGY
RIMS4 expression is associated with lymph node metastasis and poor overall survival in breast cancer
Shiqi Dong
United Kingdom
EACR26-1642
P-193
CANCER CELL BIOLOGY
PRMT7 AS KEY DRIVER OF METASTATIC PROCESS IN PROSTATE CANCER
Marina Hermosilla-Trespaderne
Spain
EACR26-1686
P-194
CANCER CELL BIOLOGY
Role of Non-coding RNA H19 in Hyperthermia-induced Chemo-sensitization in Breast Cancer
Csaba András Schvarcz
Hungary
EACR26-1688
P-195
CANCER CELL BIOLOGY
IGFBP3 regulates stem cell programs and impacts prognosis in NSCLC
Melissa Acosta-Plasencia
Spain
EACR26-1710
P-197
CANCER CELL BIOLOGY
The effects of NALCN sodium channel on the disease progression of prostate cancer.
Caitlin Bowles
United Kingdom
EACR26-1712
P-198
CANCER CELL BIOLOGY
Therapeutic Potential of TAS-115 in Patient-Derived Glioblastoma Models
Emine Yazici
Turkey
EACR26-1726
P-199
CANCER CELL BIOLOGY
CDH11 drives aggressiveness in high-grade serous ovarian cancer by modulating cell-cell and cell-ECM interactions
Antonella Tomassetti
Italy
EACR26-1740
P-200
CANCER CELL BIOLOGY
A ROS-PML-SUMO2-senescence axis involved in chemotherapy response in Acute Myeloid Leukemia
Adèle Marmuse
France
EACR26-1762
P-202
CANCER CELL BIOLOGY
In vitro transformation of primary uveal melanocyte into uveal melanoma.
Alice Darchen
France
EACR26-1770
P-203
CANCER CELL BIOLOGY
A NOVEL PD-L1-YY1 FUNCTIONAL AXIS REGULATES PROLIFERATION IN GLIOBLASTOMA
Rosetta Abate
Italy
EACR26-1774
P-204
CANCER CELL BIOLOGY
AARS1-mediated SQSTM1/p62 lactylation drives ferroptosis evasion and shapes therapeutic response in nasopharyngeal carcinoma
Weisi Wang
China
EACR26-1784
P-205
CANCER CELL BIOLOGY
Dietary timing in chronotherapy: enhancing cancer cell response to PPAR antagonists beyond circadian rhythms.
Philippine Bruno
Belgium
EACR26-1826
P-206
CANCER CELL BIOLOGY
Validation of HCT116-Derived Intestinal Organoids as a Model for Cell Death Pathway Studies
Malgorzata Adamiec-Organisciok
Poland
EACR26-1828
P-207
CANCER CELL BIOLOGY
Ferritinophagy-driven iron flux determines ferroptotic sensitivity in skin-derived cancer cells
Łukasz Cienciała
Poland
EACR26-1830
P-208
CANCER CELL BIOLOGY
Inhibition of NUDT5 Elicits Cytostatic Effects in High-Grade Glioma Cells via Disruption of Purine Nucleotide balance
Levy Gregory
United Kingdom
EACR26-1834
P-209
CANCER CELL BIOLOGY
SALL2 loss associates with aggressive colorectal cancer phenotypes and poor outcome in advanced disease
Roxana Pincheira
Chile
EACR26-1840
P-210
CANCER CELL BIOLOGY
Targeting Glutamine Metabolism: Antitumor Effects of the Glutaminase Inhibitor CB-839 in Prostate Cancer Cells
Erva Esma Yıldırım Uçarkuş
Turkey
EACR26-1848
P-211
CANCER CELL BIOLOGY
The role of glutathione in CRISPR-Cas9-modified cells
Maciej Ejfler
Poland
EACR26-1864
P-212
CANCER CELL BIOLOGY
Can photodynamic therapy-conditioning influence the stemness of endometrial cancer stem cells?
Beatriz Serambeque
Portugal
EACR26-1870
P-213
CANCER CELL BIOLOGY
Understanding the Role of APOE in Prostate Cancer
Ellie O'Sullivan
United Kingdom
EACR26-1892
P-214
CANCER CELL BIOLOGY
Autophagy Deficiency in Cancer: When the Recycling System Fails
Nikki Mutsters
Netherlands
EACR26-1896
P-215
CANCER CELL BIOLOGY
Amyloid precursor protein is increased in prostate tumour tissue and correlates with drivers of prostate cancer growth
Rachel Barker
United Kingdom
EACR26-1902
P-216
CANCER CELL BIOLOGY
Investigating the role of CDK12 in disease progression and bone metastasis in ER+ Breast Cancer
Yasmine Maati
Ireland
EACR26-1918
P-217
CANCER CELL BIOLOGY
High-Dimensional Characterization of Tertiary Lymphoid Structures
Ghislaine Lioux
United States
EACR26-2004
P-218
CANCER GENOMICS
Targeted hybrid capture with long-read sequencing accurately detects large structural variants with an optimized chemistry and workflow, using a simple downstream long-read computational analysis pipeline.
Markus Storbeck
Germany
EACR26-0080
P-220
CANCER GENOMICS
EVALUATION OF AKT1 GENE POLYMORPHISM OF PROSTATE CANCER PATIENTS IN NIGERIA
EMEKA IWEALA
Nigeria
EACR26-0084
P-221
CANCER GENOMICS
Integration of macroscopic genomic instability and microscopic fragmentation signatures defines ovarian cancer plasma profiles
Jakub Styk
Slovakia
EACR26-0206
P-223
CANCER GENOMICS
HDAC4 and the hypoxia response of leiomyosarcoma cells
Emanuele Cricchi
Italy
EACR26-0468
P-224
CANCER GENOMICS
Development of a new lncRNA therapeutic for ER+ breast cancer
Lu Wang
Australia
EACR26-0548
P-225
CANCER GENOMICS
Whole exome sequencing of early bowel polyps identifies an at-risk mutational signature in small-sized polyps
Jun Li
Australia
EACR26-0552
P-226
CANCER GENOMICS
Dissecting immune cell niches across CRC molecular subtypes through spatial transcriptomics
Arancha Cebrian
Spain
EACR26-0606
P-227
CANCER GENOMICS
Functional annotation of breast cancer risk loci implicates mammary fibroblast perturbed FILIP1L expression in breast cancer risk.
Harriet Kemp
United Kingdom
EACR26-0720
P-228
CANCER GENOMICS
Somatic landscape of high-risk non-small cell lung cancer (NSCLC) reveals comparable global profiles irrespective of germline status
Júlia Wiggeshoff
Germany
EACR26-0732
P-229
CANCER GENOMICS
Patient-derived ccRCC models preserve genomic integrity and highlight site-specific therapeutic vulnerabilities
Romika Kumari
Finland
EACR26-0848
P-230
CANCER GENOMICS
A defined genomics approach for delineating the cellular states during pancreatic cell transformation
Liangru Fei
Norway
EACR26-0870
P-231
CANCER GENOMICS
Optical Genome Mapping for detecting Homologous Recombination Deficiency in high-grade breast and ovarian cancers
Sandra Vanhuele
France
EACR26-0876
P-232
CANCER GENOMICS
Genomics and Mechanistic Insights into Fusobacterium nucleatum-Mediated Progression in HPV-Negative Oral Squamous Cell Carcinoma
Aniket Chowdhury
India
EACR26-1012
P-233
CANCER GENOMICS
Functional profiling of RNA-Dependent ERα transcriptional modulation to identify chromatin-associated molecular scaffolds as novel putative targets in breast cancer
Luigi Palo
Italy
EACR26-1044
P-234
CANCER GENOMICS
Extrachromosomal DNAs in cervical cancer contain allele-specific regulatory elements
Signe MacLennan
Canada
EACR26-1136
P-235
CANCER GENOMICS
Mapping Coordinated Multicellular Programs of Cancer Progression with Multiplexed Imaging
Loan Vulliard
Germany
EACR26-1140
P-236
CANCER GENOMICS
C/EBPβ drives thyroid cancer dedifferentiation and radioiodine resistance through IL-6/JAK/STAT and EMT activation
Kwangmin Yoo
South Korea
EACR26-1272
P-238
CANCER GENOMICS
Mapping Dormancy-Prone Cells and Microenvironmental Niches in HER2-Positive Breast Cancer
Yu-Ting Kang
Taiwan
EACR26-1314
P-239
CANCER GENOMICS
Dissecting the complex genetic landscape of familial Non-Medullary Thyroid Carcinoma through SNP genotyping, Whole-Genome Sequencing and functional screening
Daniele Puggina
Italy
EACR26-1400
P-240
CANCER GENOMICS
Molecular characterization of a potential new EWSR1-rearranged mesenchymal entity
Sergio Baute González
Spain
EACR26-1402
P-241
CANCER GENOMICS
A 100 Million Cell Single Cell Atlas Enabling Mechanistic and Genotype-Specific Drug Response Discovery
Daniela Scocchia
United States
EACR26-1406
P-242
CANCER GENOMICS
Spatial Maps of Tumor Differentiation Programs Across Histologic Architecture in Cutaneous Squamous Cell Carcinoma
Paranita Ferronika
Indonesia
EACR26-1450
P-243
CANCER GENOMICS
Elucidating the Molecular Evolution of Chemoresistance and Metastatic Potential in Bladder Cancer: A Comprehensive Study from Stepwise In Vitro Modeling to Clinical Prognosis
Sun-Hee Leem
South Korea
EACR26-1454
P-244
CANCER GENOMICS
Linking Vaccine-Related Immune Genes to Lung Cancer Susceptibility via Ultra-Rare PTVs
Balázs Koncz
Hungary
EACR26-1466
P-245
CANCER GENOMICS
A cancer cell-intrinsic program for matrix remodeling and CAF recruitment in slow-growing, poor-prognosis colorectal cancers
Anna Cassisa
Italy
EACR26-1516
P-246
CANCER GENOMICS
BUB1B and BUB3 Define a Critical G2/M Checkpoint Dependency in Malignant Pleural Mesothelioma
Ebru Kırmızıay
Turkey
EACR26-1580
P-247
CANCER GENOMICS
Temporal bulk and single‑cell transcriptomic profiling of a medulloblastoma radiotherapeutic injury model identifies targets for mitigating neurocognitive late effects
Simaran Johal
United Kingdom
EACR26-1608
P-248
CANCER GENOMICS
Single‑Cell Genomic Profiling of 218 HR+/HER2– Breast Tumours Reveals Extensive Intratumoral Genetic Heterogeneity in Early‑Stage Disease
Andrey Yurchenko
France
EACR26-1632
P-249
CANCER GENOMICS
Multiomic Characterisation of Chromosome 8q Gains In Prostate Cancer
Lucy Barton
United Kingdom
EACR26-1652
P-250
CANCER GENOMICS
A multi-tissue spatial atlas of coordinated gene expression during physiological adaptation
Lukas Paul
United States
EACR26-1758
P-251
CANCER GENOMICS
High-fidelity multiomic profiling from FFPE samples using a complete co-extraction and library preparation workflow
Anna Nieborak
United Kingdom
EACR26-1786
P-253
CANCER GENOMICS
Investigating the Carcinogenesis-Associated Genetic Landscape in Sporadic Adenomyosis: Insights from Whole Exome Sequencing
Sevcan Aydın
Turkey
EACR26-1886
P-255
CANCER GENOMICS
NOTCH inhibition is an effective differentiation-based treatment for glioblastoma
Davey Li
Canada
EACR26-1910
P-256
CARCINOGENESIS
Ovulation-Derived Extracellular Vesicles Disrupt PTEN–PI3K–AKT Signaling to Promote Fallopian Tube Epithelial Transformation
Hsuan-Shun Huang
Taiwan
EACR26-0058
P-257
CARCINOGENESIS
Aeromonas caviae Is Associated with Pancreatic Cancer and Promotes Tumor Cell Growth
Chia-Ming Yeh
Taiwan
EACR26-0140
P-258
CARCINOGENESIS
Progressive Checkpoint Kinase 1 (CHK1) expression in nonreactive, reactive mesothelial cells and pleural mesothelioma
Azadeh Asghari Birbaneh
Denmark
EACR26-0182
P-259
CARCINOGENESIS
POLQ inhibition enhances the efficacy of CP-506 in BRCA2-deficient cancer cells
Lesley Schuitmaker
Netherlands
EACR26-0894
P-260
DRUG RESISTANCE
RNA damage induced by 5-fluorouracil (5FU) – mechanisms and resolution
Zijian Zhang
United Kingdom
EACR26-0154
P-262
DRUG RESISTANCE
BQ323636.1 promotes Doxorubicin resistance in ER-positive breast cancer via IGF‑1/PI3K/mTOR/GPX4 ferroptosis suppression
Ui Soon Khoo
China
EACR26-0158
P-263
DRUG RESISTANCE
RAF1 hotspot mutations S257L and S259F confer intrinsic resistance to the RAS(ON) inhibitor daraxonrasib in melanoma
Yihang Fu
France
EACR26-0220
P-264
DRUG RESISTANCE
Metabolic heterogeneity driven by miR-203a-3p contributes to doxorubicin resistance in hepatocellular carcinoma
Noha Abdelaal
Egypt
EACR26-0228
P-265
DRUG RESISTANCE
Prospective mapping of DNA variants modulating therapy response in cancer using gene editing
Matthew Coelho
United Kingdom
EACR26-0244
P-266
DRUG RESISTANCE
Mechanisms of Resistance and Novel Therapeutic Strategies to Overcome BET Inhibitor Resistance in Pediatric Fusion-Positive Rhabdomyosarcoma
Erika Ferraro
Italy
EACR26-0258
P-267
DRUG RESISTANCE
TAp73β Enhances Sorafenib Resistance and Promotes Metastasis and Angiogenesis in Hepatocellular Carcinoma
Miray Sevinin
Turkey
EACR26-0280
P-268
DRUG RESISTANCE
Role of Primary Cilia in Targeted Therapy Resistance in Melanoma
Pietro Lugato
Italy
EACR26-0340
P-269
DRUG RESISTANCE
Sphingosine-1-phosphate receptor 3 confers tumor metastasis in lung cancer resistant to third-generation EGFR inhibitor
Hua Xie
China
EACR26-0488
P-270
DRUG RESISTANCE
Targeting Hypoxia-Driven CARM1 Overexpression Attenuates Tumor Malignancy and Chemoresistance in Colorectal Cancer
Jhao-Lin Fu
Taiwan
EACR26-0514
P-271
DRUG RESISTANCE
Sp1 as a Common Convergence Node in Resistance to EGFR and EML4ALK TKIs
Daniela Omodei
Italy
EACR26-0648
P-272
DRUG RESISTANCE
A shift from proliferation to persistence: Characterizing acquired cisplatin resistance in SCLC
Diana Piesel
Austria
EACR26-0666
P-274
DRUG RESISTANCE
Activation of tumor suppressor activity underlies reduced oncogenic capacity of colorectal cancer cells resistant to overactivation therapy
Chrysa Papagianni
Netherlands
EACR26-0734
P-275
DRUG RESISTANCE
Time-resolved interaction proteomics reveals dynamic DNA damage response programs driving gemcitabine resistance
Ying Yu Liang
Singapore
EACR26-0792
P-276
DRUG RESISTANCE
Metabolic shift to the mevalonate pathway reveals a targetable weakness in drug-tolerant BRAFV600E lung adenocarcinoma
Marine Hemmer
Belgium
EACR26-0820
P-277
DRUG RESISTANCE
Cell surface gangliosides as modulators and biomarkers of drug resistance in osteosarcoma
Maxime Grember
France
EACR26-0842
P-278
DRUG RESISTANCE
Hypoxia and extracellular matrix remodeling emerge as central features of acquired resistance to immune checkpoint blockade in colorectal cancer
Astrid Johansen
Denmark
EACR26-0898
P-279
DRUG RESISTANCE
PRC2 and MYC repression underlies oncofetal reprogramming and autophagy dependence in Colorectal Cancer
Laura Solé Font
Spain
EACR26-0918
P-280
DRUG RESISTANCE
Overcoming KRAS G12C inhibitor resistance by promoting immune-mediated elimination of resistant subpopulations
Miriam Molina-Arcas
United Kingdom
EACR26-0928
P-281
DRUG RESISTANCE
FSCN1-High Oxaliplatin Resistance in Colorectal Cancer: Imipramine-Mediated Resensitisation Without Transcript Suppression
Andrea Peréz-Sarabia
Spain
EACR26-0956
P-282
DRUG RESISTANCE
Epigenetic enhancement of cisplatin efficacy by the histone demethylase inhibitor JIB‑04 in head and neck squamous cell carcinoma (HNSCC)
Kamila Adamczuk
Poland
EACR26-1018
P-283
DRUG RESISTANCE
CD29 is associated with differential drug Responsiveness between 2D and 3D models of Triple-Negative Breast Cancer
Hyeeun Jeon
South Korea
EACR26-1024
P-284
DRUG RESISTANCE
Localized Chemotherapy Improves Tumor Control and Limits Systemic Toxicity
Vito Telebar-Zbulj
Austria
EACR26-1026
P-285
DRUG RESISTANCE
A novel patient derived cell model with sotorasib induced neuroendocrine transformation in lung adenocarcinoma
Luca Hegedüs
Germany
EACR26-1032
P-286
DRUG RESISTANCE
The therapeutic potential of Akkermansia muciniphila in the enhancement of lenvatinib response in HCC: an in vitro and in vivo study
Marco Bella
Italy
EACR26-1040
P-287
DRUG RESISTANCE
DREAM and RB deficiency confers resistance to inhibition of mitosis
Tobias Gellrich
Germany
EACR26-1046
P-288
DRUG RESISTANCE
FAK mediates therapy response and stromal pro-oncogenic signals in gastrointestinal neuroendocrine tumors
Teresa Gagliano
Italy
EACR26-1078
P-289
DRUG RESISTANCE
SCARB2 overexpression modulates chemotherapy response and phenotypic features in A2780 ovarian cancer cells
Pavol Harvanik
Slovakia
EACR26-1134
P-290
DRUG RESISTANCE
Tracking clonal dynamics through HIF2A inhibition in renal cancer
Anastasiia Kachalova
Finland
EACR26-1156
P-292
DRUG RESISTANCE
Adaptive Epigenetic Rewiring Fuels Aggressiveness in Drug Resistant Cancer Cells
Anjana Edathil Kadangodan
Israel
EACR26-1168
P-293
DRUG RESISTANCE
Regulatory crosstalk between ID1 and RUNX1 mediated by NEDD4 enhances chemoresistance in epithelial ovarian cancer
Prerna Singh
India
EACR26-1336
P-294
DRUG RESISTANCE
Inhibition of G9a histone methyltransferase allows to overcome Platinum resistance in models of Epithelial Ovarian Cancer
Francesca Basso-Valentina
Italy
EACR26-1440
P-296
DRUG RESISTANCE
Disrupting the BCL2 anti-apoptotic network restores sensitivity to chemotherapy in Triple-Negative Breast Cancer.
David Tébar-García
Spain
EACR26-1520
P-297
DRUG RESISTANCE
Phosphorylation-dependent YAP regulation following EGFR-targeted therapy in EGFR-mutant NSCLC
Mari Tienhaara
Finland
EACR26-1534
P-298
DRUG RESISTANCE
Extracellular matrix composition and fibroblast interactions modulate drug effects in colorectal cancer organoids
Adrián Orosz
Hungary
EACR26-1578
P-299
DRUG RESISTANCE
ABCF translation factors promote adaptive translational reprogramming and taxane resistance in prostate cancer
Anne Chauchereau
France
EACR26-1582
P-300
DRUG RESISTANCE
Repurposing Propranolol to Overcome Chemoresistance in Head and Neck Squamous Cell Carcinoma via β2-Adrenergic Modulation
Francesca Bruzzese
Italy
EACR26-1584
P-301
DRUG RESISTANCE
Comparative Analysis of Chemotherapy Resistance Mechanisms in Colon Cancer Cell Lines Using 2D and 3D Culture Models
Ayşe Mine Yılmaz
Turkey
EACR26-1600
P-302
DRUG RESISTANCE
Transcriptional and Chromatin Landscape Reprogramming in resistance to CDK4/6 Inhibitors in breast cancer
Claudia Fierro
Italy
EACR26-1620
P-303
DRUG RESISTANCE
Multi-omics analysis reveals dysregulated signaling pathways and therapeutic vulnerabilities in acquired panitumumab-resistant colorectal cancer
Roberta Affatato
Italy
EACR26-1716
P-304
DRUG RESISTANCE
ABCG2 transporter and Trastuzumab-Deruxtecan: Tackling Resistance and Advancing Therapeutic Strategies in HER2-positive Gastric Cancer
Serenella Pupa
Italy
EACR26-1802
P-306
DRUG RESISTANCE
Co-targeting FGFR and PI3K signaling as a strategy to overcome resistance to alpelisib/fulvestrant treatment in PIK3CA-mutant luminal A breast cancer
Melda Ozge Oguz
Turkey
EACR26-1854
P-307
DRUG RESISTANCE
KCa3.1 channel inhibition remodels the desmoplastic stroma and sensitizes pancreatic cancer to gemcitabine
Zoltán Pethő
Germany
EACR26-1908
P-308
EPIGENETICS
Integrated multi-omics analysis of transcription stress uncovers chromatin remodeling and combinatorial lethal dependencies in prostate cancer
Jing Liang
Finland
EACR26-0088
P-309
EPIGENETICS
Circularization Mechanism of Hypoxia-Induced CircSFMBT2 in Breast Cancer
Liang-Chuan Lai
Taiwan
EACR26-0128
P-310
EPIGENETICS
Analysis of the Chromatin Accessibility Landscape in Patients with Localized Prostate Cancer
Beatriz German
United States
EACR26-0200
P-311
EPIGENETICS
Methylation Fingerprints of Colorectal Cancer: From Normal Tissue to Liver and Brain Metastasis
Şuranur Ayvaz
Turkey
EACR26-0234
P-312
EPIGENETICS
DNA Methylation Profiling Identifies Epigenetic Alterations in Esophagogastric Adenocarcinoma through Enzymatic methyl-seq
Elisa Boldrin
Italy
EACR26-0246
P-313
EPIGENETICS
Lactobacillus reuteri Induces Apoptosis in HCC via SUV39H2 Modulation
Yunsang Kang
South Korea
EACR26-0572
P-314
EPIGENETICS
DNA methylation-based immune subtyping of esophageal adenocarcinoma
Rita Pinto
Norway
EACR26-0770
P-315
EPIGENETICS
Epigenetic methylation signatures in ERCP-derived samples as diagnostic biomarkers for pancreatic ductal adenocarcinoma
Marina Laplana
Spain
EACR26-0818
P-316
EPIGENETICS
Integrated Mitochondrial Clonality Analysis and Methylation Landscape Profiling Reveal Prognostic Biomarkers in Endometrial Cancer
Yusanne Yung Sing Chan
Hong Kong, China
EACR26-0826
P-317
EPIGENETICS
A DNA Methylation-Based Algorithm Distinguishing Uterine Leiomyoma from Leiomyosarcoma: Tissue Discovery with Prospective cfDNA Translation
Edyta Biskup
Denmark
EACR26-0860
P-318
EPIGENETICS
Ubiquitin-mediated stabilization of KDM5B drives chemoresistance via repression of DUSP4 in ovarian cancer
So Hee Kwon
South Korea
EACR26-0880
P-319
EPIGENETICS
Epigenetic restoration of SSTR2 enables receptor-based theranostic targeting in small cell lung carcinoma
Neeraj Kumari
Germany
EACR26-0972
P-320
EPIGENETICS
Genome-wide nanopore methylation profiling reveals epigenetic differences between differentially malignant breast cancer cell lines
Dominyka Breimelytė
Lithuania
EACR26-0986
P-321
EPIGENETICS
Selective HDAC5 Inhibition as a Combinatorial Strategy to Enhance Gemcitabine Sensitivity in PDAC
Maria Nica
Canada
EACR26-1194
P-322
EPIGENETICS
Cross-platform comparison of DNA methylation profiling and epigenetic age estimation in colorectal tissue using array-based and long-read sequencing technologies
Aliz Holczbauer
Hungary
EACR26-1376
P-323
EPIGENETICS
Interferon Regulatory Factor 4 is a Dependency and Regulator of Epigenetic Silencing in Melanoma
N. C. Tolga Emre
Turkey
EACR26-1768
P-324
EPIGENETICS
SANGUINE Project: A Minimally Invasive Methylation-Based Assay for Detection and Follow-Up of Hematologic Malignancies
Rita Haldar
Israel
EACR26-1798
P-325
EPIGENETICS
Interplay between Metabolism and Epigenetics in tumor and immune cells from human glioblastoma
Rosario Lavignolle-Heguy
France
EACR26-1944
P-326
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
A Dysadherin-Inhibitory Peptide Suppresses Hepatocellular Carcinoma through Disruption of Integrin/FAK Signaling
Hyeon-Ji Yun
South Korea
EACR26-0036
P-328
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
A Novel AR-Disrupting Peptide Induces Selective Cytotoxicity in Prostate Cancer Cells
Akanksha Agarwal
India
EACR26-0100
P-330
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Beyond conventional use: combination of loratadine, raloxifene, and sorafenib in hepatocellular carcinoma reveals novel anticancer targets
Fernanda Villarruel
Mexico
EACR26-0132
P-331
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Optimized pH-Responsive Crosslinked PROTAC Nanoparticles Enable Systemic Therapy and Survival Benefit in Orthotopic Glioblastoma and Pancreatic Cancer Models
Hiroaki Kinoh
Japan
EACR26-0178
P-332
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Mitotane-Induced Activation of the ATF4–ATF3 Axis Triggers Endoplasmic Reticulum Stress in Adrenocortical Carcinoma Cells
Aurora Schiavon
Italy
EACR26-0216
P-334
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Preclinical evaluation of loratadine and simvastatin as potential repurposing agents in combination with gefitinib and cisplatin in cervical cancer models
Tania Raya-Bahena
Mexico
EACR26-0218
P-335
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Identification of Receptor for Advanced Glycation End-products (RAGE) signaling and its downstream regulators as therapeutic target of licochalcone B in pancreatic cancer
Joshua Ko
Hong Kong, China
EACR26-0260
P-336
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Evaluation of the Anticancer Potential of a Newly Synthesized Indole-Based Compound in Gastric Cancer Cells
Ayse Busranur Celik
Turkey
EACR26-0262
P-337
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
DNA polymerase alpha inhibition sensitizes triple-negative breast cancer to cisplatin
Nadine Darwiche
Lebanon
EACR26-0268
P-338
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
A dual-targeting ScFv Antibody-Drug-Conjugate for the Treatment of Cervical Cancer
Annick van Niekerk
South Africa
EACR26-0318
P-339
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Drug repurposing for the therapy of MYC-driven pediatric tumors via mitochondrial synthetic lethality
Jan Skoda
Czech Republic
EACR26-0322
P-340
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Multiplexed single-cell drug response profiling (4iDRP) for predictive precision oncology
Arpan Kumar Rai
Switzerland
EACR26-0346
P-341
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Cabozantinib and RMC-5552 synergistically inhibit translation and OXPHOS in clear cell renal cell carcinoma
Laura EANES DA SILVA
France
EACR26-0402
P-342
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Development of Quinoxaline-Based UCHL5 Inhibitors as Novel Anticancer Agents Targeting the Proteasome System
Tae-Hee Han
South Korea
EACR26-0410
P-343
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Real-time, label-free assessment of HER2-targeted antibody-drug conjugate therapies
Johny Pires
Netherlands
EACR26-0438
P-344
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
WNT pathway mutations influence response to EGFR and BRAF inhibition in MSS BRAF-V600E metastatic colorectal cancer PDOs
Jakob Stenersen
Norway
EACR26-0442
P-345
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
In vitro study of selective inhibition of histone deacetylase 3 (HDAC3) in breast cancer cell lines
Sara Villa
Italy
EACR26-0492
P-346
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Selective Anticancer Activity of Dinitrosyl Iron Complex DNIC-OH in Oral Squamous Cell Carcinoma via Oxidative Stress–Mediated Mitochondrial Apoptosis
Shyng-Shiou Yuan
Taiwan
EACR26-0506
P-347
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Exploiting RAS/MAPK signaling dependencies in high-risk neuroblastoma through targeted inhibition
Fernando C Baltanás
Spain
EACR26-0512
P-348
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Assembloid-Based Metastasis (ABMet): A scalable model of colorectal cancer liver metastasis.
Benjamin Hershey
Switzerland
EACR26-0522
P-349
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
The nuclease EXO1 is overexpressed in tumors and promotes chemosensitization by degrading nascent DNA in BRCA-proficient cells
George-Lucian Moldovan
United States
EACR26-0534
P-350
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Analysis of YB-1 in lung squamous cell cancer tissue and cell models: gene dose, expression and inhibitor response
Noa Dürauer
Austria
EACR26-0642
P-352
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Development of a Biomarker-Based Therapeutic Approach for Pediatric Rhabdomyosarcomas
Samaneh Heydarzadeh Heris
Germany
EACR26-0652
P-353
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Evaluating the Role of HDAC1 and HDAC2 Inhibition on Cisplatin Sensitivity in Oral Squamous Cell Carcinoma
Susanna Buntrock
Germany
EACR26-0676
P-354
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
NMS-812, a clinical stage dual PERK and GCN2 modulator, with activity in Multiple Myeloma, AML and solid tumors
Claudia Perrera
Italy
EACR26-0678
P-355
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Hederasaponin B as a new compound to inhibit Sp1 transcriptional activity in oncogene-driven NSCLC
Francesca Iommelli
Italy
EACR26-0680
P-356
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
HPMA-Based EGFR-Targeting Antibody–Polymer–Drug Conjugates Enable High Drug Loading and Effective Tumor Targeting
Katerina Behalova
Czech Republic
EACR26-0704
P-357
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Atypical Distribution of the Synaptic Protein SNAP25 in High Grade Gliomas and Neuroendocrine Neoplasms
Laura Tovar-Martinez
Spain
EACR26-0758
P-358
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Novel ATSM-2-Nitroimidazole Hybrids: Addressing Solubility Limitations For Hypoxia-Directed Copper-Based Radiotheranostics
Harun Taş
Germany
EACR26-0768
P-359
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Engineering Virus-Like Particles to Cross the Blood-Brain Barrier for Targeted Glioblastoma Therapy
Ibrahim Sahin Ozyildiz
Turkey
EACR26-0772
P-360
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Dual inhibition of the mevalonate pathway synergistically suppresses ovarian clear cell carcinoma
Hengyu Zhao
Netherlands
EACR26-0774
P-361
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Store-Operated Calcium Entry Blockade Modulates Hypoxia-Induced Inflammatory Signaling and Migration in Glioblastoma Cells
Abdullah Alhamed
Saudi Arabia
EACR26-0778
P-362
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Discovery of a Natural Inhibitor Targeting the Glycolysis–Oxidative Pentose Phosphate Pathway Axis in Cancer Cells
Runjiao Zheng
South Korea
EACR26-0804
P-363
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Targeting the eIF3 Complex for Cancer Therapy: Structural Insights into eIF3a-eIF3c Interactions and Virtual Screening of Approved Drugs
Ferah Comert Onder
Sweden
EACR26-0896
P-365
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Pt1a and sorafenib combination treatment exerts synergistic anti‑hepatocellular carcinoma effect through RNA m6A methylation modification
Yinjia Huang
China
EACR26-0910
P-366
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Therapeutic targeting of oxygen sensing and SUMO protein modification pathways in renal cell carcinoma (RCC)
Iida Payne
Finland
EACR26-0930
P-367
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Hypoxia targeting augments anticancer therapy effectiveness in solid tumors
Mátyás Selmeci
Hungary
EACR26-0938
P-368
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Rewiring the Cancer Cell with Transcription Factor Degraders
Sara Boumya
Italy
EACR26-1020
P-369
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Exploiting Oncogenic Overactivation: PKC Activation as a Therapeutic Vulnerability in KRAS-Mutant PDAC
Niki Pouliopoulou
Netherlands
EACR26-1030
P-370
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Photodynamic effect of a porphyrin–triphenylphosphonium conjugate in Panc-1 cells: a 2D and 3D approach
Diana Salvador
Portugal
EACR26-1094
P-371
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Dissecting cannabinoid receptor 2 signalling in HER2+ breast cancer
Andréa Vinaga
United Kingdom
EACR26-1096
P-372
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Dual targeting of ERK5 kinase activity and nuclear translocation to beat melanoma
Elisabetta Rovida
Italy
EACR26-1102
P-373
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Evaluating synthetic lethal networks for personalised precision cancer medicine
Yuka Takemon
Canada
EACR26-1126
P-374
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
An experimental study to investigate the cellular, genetic, and molecular mechanisms of combined oral contraceptive pills in ovarian cancer.
Tanzila Saeed Ahmed Kousar
United Kingdom
EACR26-1198
P-375
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
RECOMBINANTLY ENGINEERED, SCALABLE REAGENTS FOR BIOMARKER DISCOVERY AND TARGET VALIDATION
Amy Turner
United Kingdom
EACR26-1218
P-376
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
The RAF/MEK clamp avutometinib blocks feedback-driven RAF dimerization to restore the therapeutic index of pan-RAF inhibitor combinations in RAS-mutant tumors
Christos Adamopoulos
Greece
EACR26-1224
P-377
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Proteasome-HDAC dual inhibitors as a strategy to overcome drug resistance in multiple myeloma cells
Emre Gezer
Switzerland
EACR26-1236
P-378
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Photodynamic Intervention using Temoporfin Triggers Ferroptotic Cell Death in Head and Neck Squamous Cell Carcinoma Across Varying Oxygen Gradients
Tzong-Ming Shieh
Taiwan
EACR26-1240
P-379
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Targeting epigenetic cancer driver NSD2: PROTACs, degradation mechanisms and therapeutic opportunities to overcome resistance
Dalia Barsyte-Lovejoy
Canada
EACR26-1266
P-380
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
High-throughput phenotypic drug screening and automated analysis using patient-derived organoids
Abraham Lin
Belgium
EACR26-1306
P-381
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Triple-Engineered GD2 CAR iPSC-Derived NK Cells Incorporating IL15RF-Mediated Persistence, CXCR2-Driven Tumor Homing, and B2M Knockout for Enhanced Antitumor Activity in Glioblastoma
Seung Ah Choi
South Korea
EACR26-1308
P-382
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
PARP and USP1 inhibitor combination effects in in vitro models of ovarian cancer
Stella Breininger
United Kingdom
EACR26-1362
P-383
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Targeting SHIP2 uncovers a p53-dependent therapeutic vulnerability in esophageal squamous cell carcinoma
Benjamin Beck
Belgium
EACR26-1460
P-384
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Acoustic Drug Delivery in Brain Tumors: Differential Impact of FUS Protocols on Healthy Brain Tissue and Induction of Neuronal and Astrocytic Apoptosis.
Valentin BEAUFILS*
Italy
EACR26-1478
P-385
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
The study of the toxicity and anticancer efficacy of Siramesine in Pancreatic Ductal Adenocarcinoma (PDAC) in PDX and PDOX
Fani Koutsougianni
Greece
EACR26-1488
P-386
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Dual Cytotoxic and Immunomodulatory Activity of Platinum(IV)–Flurbiprofen Hybrids in Syngeneic Models of Colon Cancer
Danijela Maksimović-Ivanić
Serbia
EACR26-1538
P-389
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Active delivery of Bortezomib-loaded SPIONs to Multiple myeloma cells via magnetic targeting
İlayda Çelik
Turkey
EACR26-1542
P-390
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
A spatial PK/PD framework predicts ADC response in solid tumors by integrating drug delivery, target engagement, and microenvironmental readiness
David Bonnel
France
EACR26-1566
P-391
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
First-in-class pharmacological inhibition of ELP3 disrupts U34 tRNA modification, rewires oncogenic translation, and suppresses tumor growth
Rosa Melvine Ndong Penda
Belgium
EACR26-1568
P-392
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
A LEFTY1 neutralizing antibody drives tumor regression in breast cancer
Nerea Ruiz de Azua
Spain
EACR26-1576
P-393
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Targeting cancer surfaceome by antibody-drug conjugates enables to combat cisplatin-resistant germ cell tumors
Adriana Fekiacova
Slovakia
EACR26-1588
P-394
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Integrative TCGA/GTEx Profiling of ADAR1‑Mediated A‑to‑I RNA Editing in Pancreatic Cancer: Tumor‑Specific Signatures, KRAS Context, and Experimental Validation
Barbara Mandriani
Italy
EACR26-1622
P-395
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
A heterotypic PDAC spheroid model reveals potassium channel modulation enhances KRAS inhibitor response
Weronika Wilczak
Germany
EACR26-1678
P-396
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Targeting oncogenic Notch signaling in Acute T-cell lymphoblastic leukemia with SERCA inhibitors
Federica Squillante
Italy
EACR26-1720
P-397
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Reversible engager proteins enable high efficiency in vivo CAR T and oncolytic virotherapy
Menachem Rubinstein
Israel
EACR26-1824
P-399
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Photoglioblaster: Dual-Triggered Phage Therapy for Precision Targeting of Glioblastoma
Elena Causa
Italy
EACR26-1868
P-400
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Bridging Preclinical Models to Clinical Application: Therapeutic mRNA for EBV-Associated Tumors
Hyewon Youn
South Korea
EACR26-1932
P-401
IMMUNOTHERAPY
Identification of Tim-3 in relation to Vγ9Vδ2T cell exhaustion in urinary bladder cancer
TERUKI SHIMIZU
Japan
EACR26-0054
P-402
IMMUNOTHERAPY
5-Azacytidine reprograms Siglec-7 and tumor-associated sialoglycans to attenuate NK cell immunity in myelodysplastic syndrome
Yuh-Ching Twu
Taiwan
EACR26-0122
P-403
IMMUNOTHERAPY
Development of Dy2O3 nanoparticles as a necrosis-mediated immune adjuvant for cancer immunotherapy
Donghyeon Yoo
South Korea
EACR26-0242
P-405
IMMUNOTHERAPY
Development of neoantigen-based DNA vaccine for brain cancer
Shih-Jen Liu
Taiwan
EACR26-0266
P-406
IMMUNOTHERAPY
Allogeneic CAR iNKT Cells Demonstrate Broad Therapeutic Activity Across Tumor and Autoimmune Disease Models
Hua Zhang
Hong Kong, China
EACR26-0294
P-407
IMMUNOTHERAPY
Peripheral immune biomarkers for predicting immunotherapy efficacy in aggressive breast cancer
Zsuzsa Kocsis
Hungary
EACR26-0312
P-408
IMMUNOTHERAPY
Preclinical Validation of a CD276xCD3 Bispecific Antibody (CC-3) for Penile Cancer
Ilona Hagelstein
Germany
EACR26-0366
P-410
IMMUNOTHERAPY
Suppression of the tumor development and progression by self-amplifying mRNA-based melanoma vaccine targeting gp100 via T cell-mediated immunity in a syngeneic mouse model
Hwayoung Na
South Korea
EACR26-0408
P-411
IMMUNOTHERAPY
Mitoxantrone-bearing HPMA-based polymeric conjugate with immunomodulatory properties for treatment of androgen-independent prostate cancer and other malignancies
Daniil Starenko
Czech Republic
EACR26-0452
P-412
IMMUNOTHERAPY
Peripheral T-cell lymphoma after CD19 CAR T-cell therapy
Ilaria Balestri
Switzerland
EACR26-0464
P-413
IMMUNOTHERAPY
Immune cell derived-exosomes repolarize neutrophils and enhance systemic T and B cell responses in triple-negative breast cancer mouse model
Yu-Diao Kuan
Japan
EACR26-0564
P-414
IMMUNOTHERAPY
Proliferative Capacity of Vδ1 T Cells Post-Expansion from Healthy Blood Donors
Amy Walsh
Ireland
EACR26-0604
P-415
IMMUNOTHERAPY
ENGINEERING SUGAR-FUNCTIONALIZED LIPID NANOPARTICLES FOR APC-TARGETED mRNA DELIVERY IN CANCER IMMUNOTHERAPY
João Panão-Costa
Portugal
EACR26-0614
P-416
IMMUNOTHERAPY
Radiotherapy synergizes with an inducible AAV-based immunotherapy platform to program local and systemic antitumor immunity
Juan Dubrot
Spain
EACR26-0698
P-417
IMMUNOTHERAPY
Distinct Roles of IL-2 Treatment for Antigen-Primed CD4⁺ and CD8⁺ T Cells: Implications for Cancer Immunotherapy
Irfan Baki Kilic
Czech Republic
EACR26-0708
P-418
IMMUNOTHERAPY
Breaking the barrier: the potential of natural killer cell immunotherapy to target pancreatic ductal adenocarcinoma
Avery P. Cook
Canada
EACR26-0712
P-419
IMMUNOTHERAPY
Differential Responsiveness of CD4⁺ and CD8⁺ T Cells to IL-2 and IL-1β Defines Complementary Cytokine Programs
Petra Weberova
Czech Republic
EACR26-0714
P-420
IMMUNOTHERAPY
CD25-biased IL-2 immunocomplexes synergize with checkpoint blockade and provide strong antitumor efficacy
Katerina Kubesova
Czech Republic
EACR26-0718
P-421
IMMUNOTHERAPY
Balancing STING Agonist-Induced Innate and Adaptive Immune Responses via Proton Channel Modulation
Minji Kim
United Kingdom
EACR26-0736
P-422
IMMUNOTHERAPY
Patient-derived organoids reveal potent and specific activity of a novel bi-specific CAR-T against high-grade glioma stem cells
Letícia Maria de Oliveira Magalhães
Brazil
EACR26-0754
P-423
IMMUNOTHERAPY
Store-Operated Calcium Entry Enhances Pro-Tumor Crosstalk Between Macrophages and Breast Cancer Cells
Mohammed Alqinyah
Saudi Arabia
EACR26-0780
P-424
IMMUNOTHERAPY
CD83 and MHC I co-localize in a perinuclear region in dendritic cells
Fang Qing Lim
Singapore
EACR26-0802
P-425
IMMUNOTHERAPY
Sapogenin-Based Nanoscale Assemblies as Immunogenic Cell Death Inducers for In Situ Vaccination Against Melanoma
Göklem Üner
Turkey
EACR26-0816
P-426
IMMUNOTHERAPY
Investigating Molecular Mimicry Between Gut Microbial and Tumour Antigens in Immune Checkpoint Inhibitor Response
Raquel Ramos
United Kingdom
EACR26-0932
P-427
IMMUNOTHERAPY
Rapid Target Selection for Personalized Cancer Vaccines Using the PEPI Panel Without Tumor Biopsy
Orsolya Lorincz
United Kingdom
EACR26-0958
P-428
IMMUNOTHERAPY
OPTIMUS: Optimising prehabilitation exercise to enhance tumour outcomes in advanced oesophageal cancer
Jamal Dirie
United Kingdom
EACR26-0968
P-429
IMMUNOTHERAPY
Tumor regression during sequential EGFR-TKI therapy following personalized peptide immunotherapy in EGFR-mutant NSCLC: a translational case report
Eszter Somogyi
United Kingdom
EACR26-0984
P-430
IMMUNOTHERAPY
PD-L1-Targeted Dual Antibody-Conjugated ATRA-Loaded Nanoparticles as a Combined Immunochemotherapeutic Strategy for Melanoma
Zeynep Islek Koklu
Turkey
EACR26-0992
P-431
IMMUNOTHERAPY
Dual analysis of CAR expression and antigen engagement with a recombinant Fc engineered reagent
Poppy Nathan
United Kingdom
EACR26-1004
P-432
IMMUNOTHERAPY
Tumor-Intrinsic SLAMF8 May Function as a Novel Immune Checkpoint in Cancer by Suppressing T Cell Activity
Mathilde L. Bagger
Denmark
EACR26-1052
P-433
IMMUNOTHERAPY
Targeting Stromal BIGH3 restores anti-tumor immunity and suppresses cachexia
Claire Crampes
France
EACR26-1084
P-434
IMMUNOTHERAPY
3D tumor spheroids support translational development of STC-1010, an off-the-shelf immunotherapy
George Alzeeb
France
EACR26-1110
P-435
IMMUNOTHERAPY
Immune-related adverse events of anti–PD-1 therapy in solid tumors: A single-center retrospective analysis
Eniko Sebestyen
Hungary
EACR26-1202
P-436
IMMUNOTHERAPY
IL-7 and CCL19 Expressing iPSC-derived NK cells to Enhance Adaptive Anti-Tumor Immunity
Hyeon Ryoo
South Korea
EACR26-1228
P-437
IMMUNOTHERAPY
Antigen-Binding Affinity Shapes Functional and Therapeutic Outcomes in GPC3-Targeted CAR-T Cells
Ungue Shin
South Korea
EACR26-1250
P-438
IMMUNOTHERAPY
Targeting mitochondria to activate immunity against multiple myeloma
Daniel Lacidogna
Italy
EACR26-1416
P-440
IMMUNOTHERAPY
Remodeling the immune microenvironment with miR-30-3p to sensitize HNSCC to immunotherapies
Ronan BERNEDE
France
EACR26-1428
P-441
IMMUNOTHERAPY
Design and evaluation of optimized off-the-shelf mRNA vaccine targeting telomerase in HLA A2-DR1 transgenic mice
Marine MALFROY
France
EACR26-1438
P-442
IMMUNOTHERAPY
From Structure to Therapy: Engineering Improved T Cell Receptors for Renal Cell Carcinoma
Oliwia Bochnacka
United States
EACR26-1498
P-444
IMMUNOTHERAPY
Jurkat T-cell antigen-independent elimination of PMA-activated SH-SY5Y Neuroblastoma cells is mediated by mTRAIL and augmented by the TrkAIII oncoprotein
Ilaria Martelli
Italy
EACR26-1510
P-445
IMMUNOTHERAPY
Leveraging Ex Vivo Tumour Models for Immune Checkpoint Inhibitor Screening
Louis Lane
United Kingdom
EACR26-1574
P-447
IMMUNOTHERAPY
Direct reprogramming mesothelioma cells into cDC1-like cells: a strategy to enhance tumor cell immunogenicity
João Soares-Gonçalves
Portugal
EACR26-1654
P-448
IMMUNOTHERAPY
CRISPR-mediated knockout of Lair1 in T cells to overcome collagen-rich solid tumor barriers in adoptive cell therapy
Nadia Kolvig Czajkowski
Denmark
EACR26-1672
P-449
IMMUNOTHERAPY
DGKα regulates antigen-induced CAR tyrosine phosphorylation, ubiquitination and cell surface expression by regulating LCK activity
Andrea Giuseppe Toscano
Italy
EACR26-1800
P-450
IMMUNOTHERAPY
CD40 agonist treatment potentiates the anti-tumor effect of tumor-derived cDC therapy in cDC therapy resistant tumor models
Sofie Deschoemaeker
Belgium
EACR26-1804
P-451
IMMUNOTHERAPY
A 61-Parameter CyTOF Panel for Comprehensive Profiling of Human PBMC to Characterize Immune Activation, Checkpoint Expression and Cytokine Signatures with Applications in Cancer Immunology
Daniela Natale
Italy
EACR26-1926
P-454
MOLECULAR AND GENETIC EPIDEMIOLOGY
The role of germline and somatic genetic testing in complex colorectal cancer predisposition
Klaudia Horti-Oravecz
Hungary
EACR26-0584
P-455
MOLECULAR AND GENETIC EPIDEMIOLOGY
Germline pathogenic variants and variants of unknown significance identified in women with ovarian tumors in a Spanish Cohort
Angelo Gamez-Pozo
Spain
EACR26-0674
P-456
MOLECULAR AND GENETIC EPIDEMIOLOGY
Machine Learning-Derived Proteomic Signatures of a Healthy Plant-Based Diet and their Mediating Role in Cancer Risk
Jihye Kim*
South Korea
EACR26-0948
P-457
MOLECULAR AND GENETIC EPIDEMIOLOGY
Founder mutation or recurrent hotspot? – Defining the origin of the CHEK2 del(ex9–10) deletion in Hungarian cancer patients
Jiazong Liu
Hungary
EACR26-1354
P-458
PREVENTION AND EARLY DETECTION
The application of liquid biopsies and artificial intelligence in cancer diagnosis and the management of cancer patients.
Ishan Gowda
United States
EACR26-0188
P-459
PREVENTION AND EARLY DETECTION
A high-fat prenatal environment and MYCN cooperates to drive neuroblastoma tumourigenesis through mitochondrial ATP synthase reprogramming
Rituparna Mittra
Australia
EACR26-0190
P-460
PREVENTION AND EARLY DETECTION
Investigating p53-mediated hepatocellular senescence as a driver of premalignant MASH and multi-organ failure
Celine Wittke
United Kingdom
EACR26-0626
P-461
PREVENTION AND EARLY DETECTION
The impact of birch-derived dietary fibre and polyphenol-rich extract on intestinal tumorigenesis in the Apcfl/fl mouse model
Anni Lantta
Finland
EACR26-0832
P-462
PREVENTION AND EARLY DETECTION
Integrated lifestyle and metabolomic profiling reveal systemic alterations in postmenopausal luminal breast cancer (LBC). BRIANNA study.
Leonor Fernández-Murga
Spain
EACR26-1062
P-463
PREVENTION AND EARLY DETECTION
Spatial Clustering of Cancer Incidence and Environmental and Socioeconomic Determinants in Bangladesh for 2015-2020
Shuvajit Das
South Korea
EACR26-1290
P-464
PREVENTION AND EARLY DETECTION
Ecological drivers of common cancers in Sri Lanka: A spatial analysis to identify determinants of cancer
Shashanka Rajapakse Mudiyanselage
South Korea
EACR26-1602
P-465
RADIOBIOLOGY / RADIATION ONCOLOGY
Targeting ferroptosis resistance to sensitise cancer cells to radiotherapy/protontherapy
Keïla Opele-Navenge
Belgium
EACR26-0284
P-466
RADIOBIOLOGY / RADIATION ONCOLOGY
Measurement of radiosensitivity in patients with cervical cancer and optimization of the RILA method.
Gyöngyvér Orsolya Sándor
Hungary
EACR26-0362
P-467
RADIOBIOLOGY / RADIATION ONCOLOGY
Multi-Model Convergence Identifies Core Radioresistance Networks and SV2A as a Candidate Biomarker in Prostate Cancer
Taha Lodhi
United Kingdom
EACR26-0404
P-468
RADIOBIOLOGY / RADIATION ONCOLOGY
Spatiotemporal Mapping of Proton Beam Radioresistance in Colorectal Cancer Liver Metastasis
Hou Wang Lam
United Kingdom
EACR26-0636
P-469
RADIOBIOLOGY / RADIATION ONCOLOGY
Dynamic transcriptional and immune trajectories distinguish radiotherapy response phenotypes in locally advanced rectal cancer
Fiza Ishaqwala
United Kingdom
EACR26-0920
P-471
RADIOBIOLOGY / RADIATION ONCOLOGY
Small extracellular vesicle-associated TGF-β and HSP70 as liquid biopsy predictors of chemoradiotherapy response in head and neck squamous cell carcinoma
Wanessa Altei
Brazil
EACR26-0976
P-472
RADIOBIOLOGY / RADIATION ONCOLOGY
A pan-cancer multi-omics meta-analysis unexpectedly associates severe hypoxia with radiotherapy benefit and enhanced extracellular matrix remodelling
Conrado Guerrero Quiles
United Kingdom
EACR26-1192
P-473
RADIOBIOLOGY / RADIATION ONCOLOGY
Mevalonate Pathway Inhibition as a Radiosensitization Strategy in Group 3 Medulloblastoma
Giorgio Avilia
Italy
EACR26-1680
P-474
RADIOBIOLOGY / RADIATION ONCOLOGY
Gold nanoparticles enhance radiosensitivity in glioblastoma cells.
Cristina Pagano
Italy
EACR26-1736
P-475
RADIOBIOLOGY / RADIATION ONCOLOGY
A Novel In Vitro Model of Bladder Cancer Radioresistance Defines a Prognostic Gene Signature Associated with ECM and Developmental Reprogramming
Conrado Guerrero Quiles
United Kingdom
EACR26-1872
P-476
SIGNALING PATHWAYS
Schwann Cell Piezo1 Mediates FGF9-Dependent Pain associated with Perineural Invasion
Romina Nassini
Italy
EACR26-0062
P-478
SIGNALING PATHWAYS
Context-specific coregulators of POU transcription factors: Mechanistic insights and implications for oncogenic transcriptional control
Aktan Alpsoy
United States
EACR26-0160
P-479
SIGNALING PATHWAYS
Transcriptional profiling of colorectal polyps reveals molecular heterogeneity beyond histological classification
Eman AlBahrani
United Kingdom
EACR26-0372
P-480
SIGNALING PATHWAYS
Targeting dysregulated Wnt/ β-catenin signaling in Gallbladder cancer
Akanksha kashyap
India
EACR26-0374
P-481
SIGNALING PATHWAYS
R-RAS2 defines a non-redundant stromal signaling program and therapeutic vulnerabilities in cancer
Cristina Díaz González
Spain
EACR26-0396
P-482
SIGNALING PATHWAYS
Differential ERK and AKT signaling plasticity underlies adaptive and genetic resistance to BRAFV600E inhibition in melanoma
Paolo Armando Gagliardi
Italy
EACR26-0430
P-483
SIGNALING PATHWAYS
Integrated Multiscale Modeling of EGFR Mutations in Lung Cancer Using Molecular Dynamics and Systems Approaches
Ai Shinobu
Japan
EACR26-0444
P-484
SIGNALING PATHWAYS
Exploring EGFR overdose as potential therapeutic approach in glioblastoma
Faiza Ahmed
United Kingdom
EACR26-0524
P-485
SIGNALING PATHWAYS
Expression the LIM Domain Containing Kinase, LIMK1, and LIMK1 Related Molecules in Pancreatic Cancer and its clinical value
David Yiran Chen
United Kingdom
EACR26-0550
P-486
SIGNALING PATHWAYS
TGF-β–induced lncRNAs regulating Smad target gene expression
Masatoshi Kitagawa
Japan
EACR26-0554
P-487
SIGNALING PATHWAYS
Transcriptomic Profiling of 3D Spheroids Reveals Structural and Metabolic Rewiring Shared by Neoplastic and Mesenchymal Cells in 3D
Maja Sabol
Croatia
EACR26-0644
P-488
SIGNALING PATHWAYS
Characterizing the Interactome of the MET Exon 14 Oncogene in Lung Adenocarcinoma
Sarah Anna Okun
Canada
EACR26-0752
P-489
SIGNALING PATHWAYS
FGFRL1-mediated influence on FGFR-AR signalling alterations in Prostate Cancer
Syeda Afshan
Finland
EACR26-0914
P-490
SIGNALING PATHWAYS
GNL3 Coordinates Androgen Receptor Activity and Immune Suppression in Castration Resistant Prostate Cancer
Edwin Cheung
Macau, China
EACR26-0916
P-491
SIGNALING PATHWAYS
Highlighting a crucial role for EGR2 mutations in the pathogenesis and BTKi resistance in CLL
Alessia Morabito
Italy
EACR26-0942
P-492
SIGNALING PATHWAYS
A Cell-Autonomous VEGFA–VEGFR1 Axis Drives Transcriptional Reprogramming and Invasive Phenotype in Melanoma
Valery Sarlo
Italy
EACR26-0954
P-493
SIGNALING PATHWAYS
Role of Akt isoforms in TGF-β1-induced EMT in NSCLC cells
Andre Menke
Germany
EACR26-0978
P-494
SIGNALING PATHWAYS
Ferroptosis in gastric cancer is affected by oncogenic ERBB3 via modulation of lipid peroxidation and GSH synthesis
Achim Aigner
Germany
EACR26-1152
P-495
SIGNALING PATHWAYS
ShcD adaptor protein drives invasion of triple-negative breast cancer cells by aberrant activation of EGFR signaling
Hayley Smith
Canada
EACR26-1190
P-496
SIGNALING PATHWAYS
Impact of cadmium and glucosamine on cellular inflammation in prostate cancer cells
Yuh-Lin Wu
Taiwan
EACR26-1244
P-497
SIGNALING PATHWAYS
High aggressiveness prostate cancer cells decrease survival, proliferation, and differentiation processes in a GPER dependent manner
Jorge Adrian Ramirez de Arellano Sanchez
Mexico
EACR26-1262
P-498
SIGNALING PATHWAYS
MECHANISTIC EFFECTS OF KARANJIN IN SKIN CANCER
EPSITA MUKHERJEE
India
EACR26-1286
P-499
SIGNALING PATHWAYS
Signalling mechanisms of small cell lung cancer plasticity
Martin J Baker
United Kingdom
EACR26-1390
P-500
SIGNALING PATHWAYS
LEFTY1 drives breast cancer progression by enabling escape from BMP-mediated growth suppression
Nerea Ruiz de Azua
Spain
EACR26-1514
P-501
SIGNALING PATHWAYS
Sarcopoterium spinosum root extract reduces PRR-driven inflammatory signaling in lung cancer models
Namrata Maity
Israel
EACR26-1554
P-502
SIGNALING PATHWAYS
Transcription factor mediated rewiring of transcriptional programs in colorectal cancer
Minh Chau Luong Boi
Netherlands
EACR26-1606
P-503
SIGNALING PATHWAYS
CircRNA Remodeling in Lung Cancer Cells Infected with Staphylococcus aureus
Ufuk Mert
Turkey
EACR26-1614
P-504
SIGNALING PATHWAYS
MAPK agonism is a therapeutic vulnerability of Ewing sarcoma
Amber Amparo
Netherlands
EACR26-1748
P-506
SIGNALING PATHWAYS
Hyperactivated ERK Signaling Sustains mTORC1 Activity in Malignant Melanoma under Amino Acid Deprivation
Stjepan Uldrijan
Czech Republic
EACR26-1894
P-507
TRANSLATIONAL RESEARCH
Evaluation of Lymph Node Status through Virtual 3D Histology using X-Rays
Marius Reichardt
Germany
EACR26-0056
P-508
TRANSLATIONAL RESEARCH
Blockade of the NAD+ salvage pathway synergizes with irinotecan in chemo-resistant microsatellite stable colorectal cancer models
Mariangela Russo
Italy
EACR26-0394
P-510
TRANSLATIONAL RESEARCH
Bone Marrow Stromal Cells Drive Resistance to B-Cell Receptor Signaling Targeted Agents in B-Cell Non-Hodgkin Lymphoma
Alex Zadro
Switzerland
EACR26-0398
P-511
TRANSLATIONAL RESEARCH
Dissecting Response and Resistance to Trastuzumab deruxtecan in ER-Positive Breast Cancer
Elodie Montaudon
France
EACR26-0436
P-512
TRANSLATIONAL RESEARCH
3D cancer models to follow cell-specific killing after low-dose of chemotherapeutic agents in combination with immune therapies
Boye Nielsen
Denmark
EACR26-0580
P-514
TRANSLATIONAL RESEARCH
Preclinical evaluation of trastuzumab deruxtecan in HER2-expressing prostate cancer xenograft models: Implications for therapeutic expansion beyond traditional HER2-positive cancers
Jenny Worthington
United Kingdom
EACR26-0610
P-515
TRANSLATIONAL RESEARCH
Pesticide Exposure and Breast Cancer: Integrative Evidence from a Decade of Studies in a Brazilian Rural Landscape.
Carolina Panis
Brazil
EACR26-0620
P-516
TRANSLATIONAL RESEARCH
HPV Status Shapes the Therapeutic Rationale for Bispecific Antibodies in R/M HNSCC
Ilenia Rolli
Italy
EACR26-0684
P-517
TRANSLATIONAL RESEARCH
Brain tumor border and core tissue analysis of monopolar-induced volatolome with mass spectrometry
Ismaïl Hermelo
Finland
EACR26-0740
P-519
TRANSLATIONAL RESEARCH
GLP-1 Receptor Agonist Reduces Anthracycline– and Trastuzumab–Induced Cardiac Dysfunction and Systemic hs-CRP, IL-1β and IL-6 in Non-Diabetic Preclinical Models
Pietro Forte
Italy
EACR26-0776
P-520
TRANSLATIONAL RESEARCH
DAC-1522, a Trop2-directed degrader-antibody conjugate, overcomes resistance to conventional ADCs
Xuan Zhang
China
EACR26-0790
P-521
TRANSLATIONAL RESEARCH
Development of miniaturized processes to predict response to cancer treatments and guide therapeutic decision-making using patient-derived ovarian tumor organoids
Chloé MARDE ALAGAMA
France
EACR26-1016
P-522
TRANSLATIONAL RESEARCH
High-Throughput Automated Organoid-Based Chemosensitivity Profiling Maps the Drug Response Landscape for Precision Oncology in Cholangiocarcinoma
Hui Bai
China
EACR26-1022
P-523
TRANSLATIONAL RESEARCH
Prostatic Solitary Fibrous Tumour: A Two-Case Series Highlighting Diagnostic Complexity and Surgical Decision-Making in a Rare Pelvic Neoplasm
Julius Angeles Bullo
United Kingdom
EACR26-1060
P-524
TRANSLATIONAL RESEARCH
Matrix-Based Tissue-Engineered Human 3D Tumor Models for Predictive Preclinical Anti-Cancer Therapy Evaluation
Maximiliane Wussmann
Germany
EACR26-1082
P-525
TRANSLATIONAL RESEARCH
First-in-man multimodal imaging of autologous T-cell trafficking in rectal cancer using ex vivo nanoparticle labelling and quantitative fluorescence endoscopy plus 19F MRI.
Robbin de Kruijf
Netherlands
EACR26-1148
P-526
TRANSLATIONAL RESEARCH
“Defense in Disguise”: Biodistribution and Toxicity Profiling of RBC Membrane-Camouflaged Nanoparticles for Cancer Theranostics
Sarmistha Mazumder
India
EACR26-1274
P-528
TRANSLATIONAL RESEARCH
TransPillar-based Uniform and Reproducible Lung Cancer Organoids for Anticancer Drug Sensitivity Assessment
Chan Kwon Park
South Korea
EACR26-1282
P-529
TRANSLATIONAL RESEARCH
Enabling Transcriptome-Wide Single Cell RNA Sequencing from FFPE Tissues with Evercode WT Combinatorial Barcoding
Gokhan Demirkhan
United States
EACR26-1412
P-531
TRANSLATIONAL RESEARCH
Ultra-High-Plex Cyclic Immunofluorescence enables Comprehensive Spatial Proteomic Profiling of the Tumor-Immune Microenvironment
Jannik Boog
United States
EACR26-1470
P-532
TRANSLATIONAL RESEARCH
Translational validation of modulated electro-hyperthermia impulse mode: Superior anti-tumor efficacy over continuous mode in a Triple Negative Breast Cancer model
Dániel Bócsi
Hungary
EACR26-1518
P-533
TRANSLATIONAL RESEARCH
Integrated Genomic and Functional Evaluation of PTK7-ADC in BC-PDEs Identifies CNV Amplification–Associated Resistance and Stage-Specific PTK7 Expression–Dependent Apoptosis
Hina Zamir
United Kingdom
EACR26-1560
P-534
TRANSLATIONAL RESEARCH
Manipulating H3K27 methylation affects cancer cell survival after hyperthermal chemotherapy in a p53-dependent manner
Mary Kennedy
Germany
EACR26-1658
P-535
TRANSLATIONAL RESEARCH
Z1362873773 (Z773) and NP-G2-044 differentially modulate breast cancer cell migration despite distinct cytotoxic profiles
Fátima Postigo-Corrales
Spain
EACR26-1752
P-538
TRANSLATIONAL RESEARCH
Collagen architecture in head and neck squamous cell carcinomas as biomarker of resistance to anti-PD1
Ellen Van Obberghen-Schilling
France
EACR26-1852
P-539
TRANSLATIONAL RESEARCH
Evaluation of response to doxorubicin treatment in a 3D osteosarcoma cell culture model: Experimental and mathematical modeling studies
Marija Pavlović
Serbia
EACR26-1882
P-541
TRANSLATIONAL RESEARCH
Direct In Situ Detection of Oncogenic Mutations in FFPE Tissue for Clinical Pathology Workflows
Hower Lee
Sweden
EACR26-1934
P-543
TUMOUR BIOLOGY
EGFR-Dependent RYK–GSK3β Signaling Sustains Cancer Cell Survival and Sonic Hedgehog Production in Gemcitabine-Resistant Pancreatic Cancer Cells
Kiran Yadav
South Korea
EACR26-0076
P-645
TUMOUR BIOLOGY
RNF126-Driven Anoikis Resistance and Peritoneal Colonization in Ovarian Cancer
Duc Anh Vu
Japan
EACR26-0078
P-646
TUMOUR BIOLOGY
Development of novel treatment strategies based on investigations into the molecular pathobiology of adenosquamous gastric cancer.
Carla Portulano
Germany
EACR26-0090
P-647
TUMOUR BIOLOGY
A PDX Platform Supporting the Development of Next-Generation KRAS Inhibitors
Bigot Ludovic
France
EACR26-0098
P-648
TUMOUR BIOLOGY
ULK1-mediated SNAP23 phosphorylation drives oncogenic small extracellular vesicles (sEV) biogenesis in Hepatocellular Carcinoma (HCC)
Wan Ki Wong
Hong Kong, China
EACR26-0104
P-649
TUMOUR BIOLOGY
Granulin Precursor (GRN) Links Notch and ERBB Signalling to Prognosis in Clinical Breast Cancer
Zhuokai Sun
United Kingdom
EACR26-0150
P-650
TUMOUR BIOLOGY
PICH Maintains Genome Stability and Promotes Colorectal Cancer Cell Survival: Synthetic Lethality of Topoisomerase II Inhibitors in PICH-Deficient Tumors
Kun CHEN
Hong Kong, China
EACR26-0194
P-651
TUMOUR BIOLOGY
Investigation of the interaction between DR5-AS long non-coding RNA and CAPRIN1 protein in cervical cancer cells
Bunyamin Akgul
Turkey
EACR26-0196
P-652
TUMOUR BIOLOGY
Oncogene stability via long noncoding RNAs as a therapeutic strategy
Yu-Ru Lee
Taiwan
EACR26-0232
P-653
TUMOUR BIOLOGY
Smad2/3 blockade delivers dual anti-fibrotic and anti-tumor effects by disrupting an IPF-driven TGF-β–SLUG–TRIM31–TAK1–ERK proliferative axis in KRAS-mutant NSCLC
Jiyoun Kim
South Korea
EACR26-0236
P-544
TUMOUR BIOLOGY
Fusion between Macrophages and Cancer Cells Contributes to Metabolic Reprogramming and Distant Progression via SET/PP2A
Hui Ju Chang
Taiwan
EACR26-0238
P-545
TUMOUR BIOLOGY
Locally produced GPCR agonists enable melanoma proliferation in the lungs
Lola Monmasson
France
EACR26-0272
P-654
TUMOUR BIOLOGY
MAOB-induced ROS-dependent DNA damage engages a cyclic MAOB–HNF1A–53BP1–p53 regulatory axis suppressing malignant phenotypes in clear cell renal cell carcinoma
Ming-Hsien Chien
Taiwan
EACR26-0296
P-656
TUMOUR BIOLOGY
A Systems Biology Approach to Identify Propolin C as a Multi-target Inhibitor of ER-driven Tumour Progression and Endocrine Resistance in Breast Cancer Cells
Meng-Shih Weng
Taiwan
EACR26-0298
P-657
TUMOUR BIOLOGY
FLRTing with cholangiocarcinoma: FLRT3 promotes proliferation and modulates the tumor phenotype
Lara Prates
Belgium
EACR26-0314
P-546
TUMOUR BIOLOGY
Polyploid Giant Cancer Cells as Potential Targets to Overcome Resistance in High Grade Serous Ovarian Carcinoma
Anu Anil
Finland
EACR26-0326
P-547
TUMOUR BIOLOGY
Leveraging endogenous DNA damage in therapy resistant ovarian cancer
Srividhya Sundaresan
Finland
EACR26-0328
P-548
TUMOUR BIOLOGY
Regional biology of the normal colon shapes tumour evolution in GEMMs
Jessica Edwards
United Kingdom
EACR26-0334
P-658
TUMOUR BIOLOGY
Oncomicrobiota profiles in pancreatic ductal adenocarcinoma
Lucia Trilla-Fuertes
Spain
EACR26-0360
P-659
TUMOUR BIOLOGY
Inhibition of ADAM9 reverses immune suppression and attenuates lung tumor progression
Yuh-Pyng Sher
Taiwan
EACR26-0414
P-661
TUMOUR BIOLOGY
Intra-pancreatic adipose tissue drives immune evasion in pancreatic cancer
CHENGCHENG WANG
China
EACR26-0418
P-549
TUMOUR BIOLOGY
Long-Term Tamoxifen Promotes Lung Metastasis in Breast Cancer via Lipid-Driven Fibrotic Niche Formation
SeungSu Kim
South Korea
EACR26-0420
P-662
TUMOUR BIOLOGY
Decoding early malignant transitions in nevus-associated melanoma in space and time
Svea Beier
Germany
EACR26-0432
P-663
TUMOUR BIOLOGY
Differential miRNA Expression and KEGG Signaling in U87 and HS683 Glioma Cells: A Comparison of 2D and 3D Culture Systems
Rima Miknaitė
Lithuania
EACR26-0446
P-550
TUMOUR BIOLOGY
The Effect of Alkaline Extracellular pH and Its Combination with Doxorubicin and Vitamin C on Colorectal Cancer
Nazha Ghaleb
Lebanon
EACR26-0454
P-664
TUMOUR BIOLOGY
Genetic driver–induced epithelial state continuum unleashes colorectal cancer metastasis
Gabriele Diamante
Germany
EACR26-0456
P-665
TUMOUR BIOLOGY
Mitochondrial transfer from Melanoma to Natural Killer cells as a novel immune evasion strategy
Lourdes Harting
Chile
EACR26-0482
P-666
TUMOUR BIOLOGY
Oncogenic roles of a microRNA and its downstream mechanisms in colorectal cancer
Sarang Kim
South Korea
EACR26-0484
P-667
TUMOUR BIOLOGY
Collagen-Dependent IL-1β Reprogramming Drives LRRC15⁺ Immunosuppressive CAF Differentiation in Pancreatic Ductal Adenocarcinoma
Chieh Shen
Taiwan
EACR26-0556
P-668
TUMOUR BIOLOGY
Expression Profile and Prognostic Significance of N6-methyladenosine RNA Methylation Key Regulators in Pediatric T-cell acute Lymphoblastic Leukemia
Minu Singh
India
EACR26-0568
P-551
TUMOUR BIOLOGY
In vitro Evaluation of the Effects of Donafenib on TMZ-Resistant Glioblastoma and Microglia Polarization
Ece Oylumlu
Turkey
EACR26-0594
P-552
TUMOUR BIOLOGY
Chemotherapy-Induced Translational Rewiring Enables Drug-Tolerant Persister Exit and Tumor Relapse
Laura Jentschel
France
EACR26-0598
P-669
TUMOUR BIOLOGY
Hypoxia-Remodeled Extracellular Matrix Orchestrates T Cell Dysfunction and Tumor Immunosuppression
Kevin James Baker
Denmark
EACR26-0600
P-553
TUMOUR BIOLOGY
CAF-expressed YB-1 is required for stimulation of mesothelioma growth
Michael Grusch
Austria
EACR26-0628
P-554
TUMOUR BIOLOGY
Association of long non-coding RNAs NRAD1 and CRNDE with colorectal cancer progression
Alexandra Repáková
Slovakia
EACR26-0630
P-670
TUMOUR BIOLOGY
Antiandrogen drugs target Cajal bodies to reprogram RNA regulation in prostate cancer cells
Minttu Kärkkäinen
Finland
EACR26-0656
P-555
TUMOUR BIOLOGY
Melanoma-reprogrammed fibroblasts promote tumor aggressiveness and immune escape
Melissa Chapeau
France
EACR26-0660
P-556
TUMOUR BIOLOGY
Metastatic Mechanism: SASH1 - Rac1 interaction controls collective cell migration in colorectal carcinoma
Max Umbach
Germany
EACR26-0692
P-557
TUMOUR BIOLOGY
m6A Regulates Cytotoxic T cell Effector Function
Leona Brandl
Germany
EACR26-0702
P-558
TUMOUR BIOLOGY
Microenvironment-dependent control of apoptosis through deep BCL2-family modulation in B-cell lymphoma
David Chiron
France
EACR26-0722
P-559
TUMOUR BIOLOGY
Effect of NRP1 inhibitors on a 3D medulloblastoma model
Lysiane LESSURE
France
EACR26-0762
P-561
TUMOUR BIOLOGY
Time-dependent immune reprogramming defines an immunosuppressive window in early postpartum breast cancer
Regina Peña-Enríquez
Spain
EACR26-0782
P-562
TUMOUR BIOLOGY
Reduced TSG-6 expression under M1 macrophage induced inflammatory conditions drives chemoresistance and is associated with poor prognosis in melanoma
Sanna Pasonen-Seppänen
Finland
EACR26-0784
P-563
TUMOUR BIOLOGY
Fluorescent detection of oncogenic splice variants and short targets using a spatial multiomic assay
Anushka Dikshit
United States
EACR26-0786
P-564
TUMOUR BIOLOGY
The Human Antigen R is a key determinant of cancer cells proliferation and adaptation to hypoxia in neuroblastoma.
Noemie Legrand
France
EACR26-0836
P-566
TUMOUR BIOLOGY
Characterization of new syngeneic models of oncogenic addiction to mutant EGFR
Mathilde Goupil
France
EACR26-0850
P-567
TUMOUR BIOLOGY
Patient-inspired engineering of the breast cancer lung metastatic microenvironment to identify targetable vulnerabilities
Laura Fallert
Spain
EACR26-0886
P-568
TUMOUR BIOLOGY
Targeted protein degradation models for the exploration of spliceosome-associated RNA helicases as therapeutic targets
Caitlin Davies
United Kingdom
EACR26-0924
P-569
TUMOUR BIOLOGY
Spatial and liquid biopsy-based characterization of cholangiocarcinoma immunophenotypes
Mar Teixidó
Spain
EACR26-0980
P-570
TUMOUR BIOLOGY
Integrated single-cell analysis reveals a novel perforin function in pericytes of human brain tumors
Benoît Duc
Switzerland
EACR26-0988
P-571
TUMOUR BIOLOGY
lncRNA NRAD1 reprograms chromatin accessibility and transcriptional networks in breast cancer
Hannah Cahill
Canada
EACR26-1050
P-572
TUMOUR BIOLOGY
ADAMTS2 in cancer: from tumour growth inhibition to increased metastatic dissemination
Louis Stock
Belgium
EACR26-1056
P-573
TUMOUR BIOLOGY
Adipocytes as Active Stromal Partners in Triple-Negative Breast Cancer progression
Tiziana Triulzi
Italy
EACR26-1064
P-574
TUMOUR BIOLOGY
Prostaglandin I2 receptor is a CAF-specific tumor suppressor in HCC and PDAC
Tommy Chastel
France
EACR26-1068
P-575
TUMOUR BIOLOGY
Contact-dependent horizontal protein transfer as a mechanism of stromal support for leukemia cells
Laura Turos-Korgul
Poland
EACR26-1080
P-576
TUMOUR BIOLOGY
Robust multiplex cytokine profiling in second-generation humanized NOG mice using a 41-plex humanized mouse immune panel: Cross-donor validation and implications for translational oncology studies
Mette Harboe
Denmark
EACR26-1130
P-577
TUMOUR BIOLOGY
Defining a stability window for long-term, dense T47D tumour spheroids under repeated polymeric nanoparticle exposure.
Robbin de Kruijf
Netherlands
EACR26-1142
P-578
TUMOUR BIOLOGY
Cytoplasmic 5hmC reveals TET3-linked RNA processing programmes in triple-negative breast cancer
Biancastella Cereser
United Kingdom
EACR26-1150
P-580
TUMOUR BIOLOGY
Histopathology of Prostate Cancer Bone Metastases Associates with Bone Alterations and Distinct Tumor Microenvironment Patterns
Bita Mojtahedzadeh
Canada
EACR26-1188
P-581
TUMOUR BIOLOGY
Trop-2 loss remodels breast cancer cell interactions with the extracellular matrix
Lukáš Peřina
Czech Republic
EACR26-1200
P-582
TUMOUR BIOLOGY
Unraveling prostate cancer bone metastasis biology through translational organoid systems
Zora Baumann
Switzerland
EACR26-1208
P-583
TUMOUR BIOLOGY
Modeling Oligodendroglioma in Three Dimensions: Self-Assembled Tumor Spheroids
Raquel Morales-Gallel
Spain
EACR26-1222
P-584
TUMOUR BIOLOGY
Targeting LINC01929 upregulates immunoproteasome activity in breast cancer.
Bakhmala Khan
Canada
EACR26-1270
P-585
TUMOUR BIOLOGY
Therapeutic Restoration of p53 Function via AMO-Mediated Splicing Correction in p53 K120R mutation
Han-Byul Jung
South Korea
EACR26-1276
P-586
TUMOUR BIOLOGY
A novel ex vivo bone metastasis culture platform for triple-negative breast cancer
Tiina Kähkönen
Finland
EACR26-1292
P-588
TUMOUR BIOLOGY
Validation of a preclinical Bone Metastasis Technology Platform against clinically used standard-of-care therapies in mice
Tii Kähkönen
Finland
EACR26-1296
P-589
TUMOUR BIOLOGY
Immunological and prognostic significance of stromal fibronectin and tenascin-C in colorectal cancer
Vilja V. Tapiainen
Finland
EACR26-1298
P-590
TUMOUR BIOLOGY
Genetic inactivation of the histone modifying enzyme Kmt2c/MLL3 in a mouse model of melanoma impairs tumor growth and metastasis
Apostolos Klinakis
Greece
EACR26-1300
P-591
TUMOUR BIOLOGY
Temporal Dynamics of LINE-1 Retrotransposon in High-Grade Serous Ovarian Cancer Genomes
Fatih Genç
Finland
EACR26-1330
P-593
TUMOUR BIOLOGY
LGALS3BP as a regulator of selective sorting of cargo into Extracellular Vesicles in Neuroblastoma
Ilaria Cela
Italy
EACR26-1346
P-594
TUMOUR BIOLOGY
Using patient-derived tumoroids to explore the role of AXL receptor tyrosine kinase in colorectal cancer
Pedro Morata Saldaña
Austria
EACR26-1356
P-595
TUMOUR BIOLOGY
AI-Accelerated FFPE Proteomics Reveals ATP5IF1-Driven Mitochondrial Remodeling in Acral Melanoma
Diana Lashidua Fernández-Coto
Mexico
EACR26-1358
P-596
TUMOUR BIOLOGY
Multiscale insights into the divergence of Go and Grow phenotypes in glioblastoma
Víctor Montosa Micó
Spain
EACR26-1360
P-597
TUMOUR BIOLOGY
Partial BRG1 loss by immunohistochemistry in brain metastatic small cell lung carcinoma
Fatime Szalai
Hungary
EACR26-1378
P-598
TUMOUR BIOLOGY
Impact of Metabolic Liver Microenvironment on c-Met Signaling in HCC
Ezgi Bağırsakçı Tepe
Turkey
EACR26-1386
P-599
TUMOUR BIOLOGY
Integrated Multi-Omics Analysis Reveals the Metabolic and Molecular Landscape of Pancreatic and Ileal Neuroendocrine Tumors
Sofia Dellavalle
Italy
EACR26-1396
P-600
TUMOUR BIOLOGY
Integrative Proteomics and AI-Driven Digital Pathology Enable Clinical Stratification in Melanoma: Insights from the MEGA-Study
Leticia Szadai
Sweden
EACR26-1398
P-601
TUMOUR BIOLOGY
TGFβ signaling and loss of mast cell activity contribute to poor outcome of right-sided colon cancer
Blanca García-Micó
Spain
EACR26-1408
P-602
TUMOUR BIOLOGY
Transcriptomic identification and functional targeting of key drivers of M2 macrophage polarization in gastric cancer
Alba Aguilar-Cifre
Spain
EACR26-1420
P-603
TUMOUR BIOLOGY
Hypoxia-induced quiescence protects tumor cells against radiation-induced cell death
Apostolos Menegakis
Netherlands
EACR26-1422
P-604
TUMOUR BIOLOGY
Dissection of Platelets and Coagulation Genes’ Mechanisms in Kidney Cancer Metastasis (PlaCoMets)
Jessica Carvalho Videira
Spain
EACR26-1424
P-605
TUMOUR BIOLOGY
Mural β3-Integrin Signposts a Stromal Gene Signature That Identifies Increased Recurrence in Oncotype DX Low-Risk Breast Cancer
Alex Jordan
United Kingdom
EACR26-1448
P-606
TUMOUR BIOLOGY
Myeloid cell heterogeneity reveals pro- and anti- metastatic phenotypes in breast cancer metastasis
Juliane Winkler
Austria
EACR26-1458
P-607
TUMOUR BIOLOGY
Into the third dimension: modeling early glioma progression in neural organoids
Chiara Riviera
Italy
EACR26-1480
P-608
TUMOUR BIOLOGY
Antitumor Effects of TAS-115 in Glioblastoma: Evidence from In vitro and In vivo Models
Aleyna Gezen
Turkey
EACR26-1486
P-609
TUMOUR BIOLOGY
Novel Insights into Hypoxia-Driven Transcriptomic and Epigenetic Landscapes in Grade 3 Meningioma
Mansi Dalal
India
EACR26-1490
P-610
TUMOUR BIOLOGY
Life After Death: Apoptosis-Induced Proliferation As A Target For Colorectal Cancer Therapy
Marija Mojic
Serbia
EACR26-1526
P-611
TUMOUR BIOLOGY
Differential CD63 and Annexin V Expression on Extracellular Vesicles Reflects Aggressiveness in Patient-Derived Mesothelioma Cell Lines
Nikolett Kitti Dobos
Hungary
EACR26-1528
P-612
TUMOUR BIOLOGY
RPL5 Drives Mutant p53 Stabilization and Drug Resistance via MDM2-A Isoform Switching in Triple-Negative Breast Cancer
Da Sol Kim
South Korea
EACR26-1558
P-614
TUMOUR BIOLOGY
CAF Differentiation Trajectories Define Clinically Distinct Stromal Programs in HBV-Related Hepatocellular Carcinoma
Doyeong Kim
South Korea
EACR26-1562
P-615
TUMOUR BIOLOGY
High-resolution integrative analysis allows characterization and spatial annotation of normal and cancer-associated colon fibroblasts
Saara Ollila
Finland
EACR26-1610
P-616
TUMOUR BIOLOGY
Modelling Epithelial-Fibroblast Crosstalk in Early Squamous Lung Cancer Using a Multilineage Complex Co-culture System
Alice Chernaik
United Kingdom
EACR26-1628
P-617
TUMOUR BIOLOGY
Distinct Spatial Immune Organization and CD147-Driven Microglial Reprogramming in TNBC versus HER2+ Brain Metastases
Federica Toma
Italy
EACR26-1636
P-618
TUMOUR BIOLOGY
Integrated spatial multiomics profiling with GeoMx Whole Transcriptome Atlas (WTA) and 1,200+ Discovery Proteome Atlas (DPA) maps key tumor and immune programs in Colorectal Cancer
Irene Yujnovsky
France
EACR26-1648
P-619
TUMOUR BIOLOGY
Tannat Grape Pomace Compounds Mitigate Changes Induced by Advanced Glycation End Products in 3D Breast Epithelial Cultures
Lucia Pastro Cardoso
Uruguay
EACR26-1660
P-620
TUMOUR BIOLOGY
Targeting CD147 impairs tumor growth and alters microenvironmental spatial organization in H3 K27-altered diffuse midline glioma
Rita Colonna
Italy
EACR26-1692
P-621
TUMOUR BIOLOGY
Myo-Tumour: A novel role for skeletal muscle in tumour growth and proliferation
Laura Cussonneau
Italy
EACR26-1694
P-622
TUMOUR BIOLOGY
The role of periostin in pancreatic cancer
Caitlin Alder
United Kingdom
EACR26-1730
P-623
TUMOUR BIOLOGY
Cell-cell interactions between Mesenchymal Stromal Cells and B-ALL cells reduce PTL and DMAPT cytotoxicity and promote an inflammatory microenvironment.
Yesica Beltran Calderon
Mexico
EACR26-1732
P-624
TUMOUR BIOLOGY
Remodeling of the Normal Mesenchymal Microenvironment Following Interaction with B-Cell Acute Lymphoblastic Leukemia Cells
Jesus Lopez Cervantes
Mexico
EACR26-1756
P-625
TUMOUR BIOLOGY
Development of an immunocompetent murine model of glioblastoma expressing human EGFRvIII
Agnese Vincenzi
Italy
EACR26-1792
P-626
TUMOUR BIOLOGY
Non-canonical ORF-derived HLA class I peptides are prominent in chromosomally unstable cancer
Aglaia Skolariki
United Kingdom
EACR26-1794
P-627
TUMOUR BIOLOGY
Spatial PD 1/PD L1 Interaction Profiling Across Immune Cell Populations Using a Unique Protein Proximity Assay and Simplified TSA IF Multiplexing
Mikael Malmqvist
Sweden
EACR26-1796
P-628
TUMOUR BIOLOGY
FAM3C/ILEI as a prognostic marker and therapeutic target in head and neck and cutaneous squamous cell carcinoma
Agnes Csiszar
Austria
EACR26-1806
P-629
TUMOUR BIOLOGY
Doxorubicin-Induced Cardiotoxicity Promotes Metastatic Relapse in Osteosarcoma
Gabriela Sampaio-Ribeiro
Portugal
EACR26-1810
P-630
TUMOUR BIOLOGY
Cellular decomposition and metabolic profiling of the tumour microenvironment tumour-stroma interface using high-dimensional spatial proteomics and image analytics.
Kai Bouché-Zurhove
United States
EACR26-1850
P-633
TUMOUR BIOLOGY
Spatial immunometabolic profiling of non-small cell lung cancer reveals distinct immune exclusion patterns and functional niches
Kai Bouché-Zurhove
United States
EACR26-1880
P-634
TUMOUR BIOLOGY
Molecular rewiring leading to bladder cancer tumorigenesis
Md Kaykobad Hossain
Norway
EACR26-1888
P-635
TUMOUR BIOLOGY
Angiogenesis and angiogenic inhibitors in human renal cell cancer with special reference to mast cell and tryptase
Giovanni Mastrandrea
Italy
EACR26-1916
P-636
TUMOUR BIOLOGY
New Advances in AI-Empowered Tissue Cytometry and Precision Medicine
Rupert Ecker
Australia
EACR26-1922
P-638
TUMOUR BIOLOGY
Interpreting Translational Insights from Mouse Model to Human Tumors Using Imaging Mass Cytometry
Daniela Natale
Italy
EACR26-1924
P-639
TUMOUR BIOLOGY
A stromal RAS–PI3K switch controls CAF fate and tumor-supportive matrix architecture in lung cancer
Esther Castellano
Spain
EACR26-1936
P-640
TUMOUR BIOLOGY
Loss of vimentin promotes cell migration and tumor progression in endometrial cancer
Camilla Krakstad
Norway
EACR26-1938
P-641
TUMOUR BIOLOGY
Myofibroblastic cancer-associated fibroblasts are associated with NK cell exhaustion in head and neck cancer
Maria Fernanda Rodrigues
Brazil
EACR26-1940
P-642
TUMOUR EVOLUTION AND HETEROGENEITY
Analysis, imaging and sorting of 3-D tumor spheroids on the COPAS VISION large particle flow cytometer
Giuliano Ferrero
Belgium
EACR26-0214
P-671
TUMOUR EVOLUTION AND HETEROGENEITY
Subclonal β-catenin heterogeneity boosts ovarian cancer metastasis through a senescence-associated secretory phenotype driven by Hippo/YAP signaling pathway in an O-GlcNAcylation-dependent manner
Yang Yibin
Hong Kong, China
EACR26-0624
P-672
TUMOUR EVOLUTION AND HETEROGENEITY
Biosynthetic Persister States and Metabolic Plasticity Fuel Recurrence
Antonio Gentilella
Spain
EACR26-0806
P-673
TUMOUR EVOLUTION AND HETEROGENEITY
DNA barcoding to trace resistance/persistance to EGFR inhibition in lung cancer cells
Luca Grumolato
France
EACR26-0846
P-674
TUMOUR EVOLUTION AND HETEROGENEITY
Keratin 6-Keratin 14 (V7) Fusion Drives Cell Fusion and Cell-in-Cell Formation in Oral Squamous Cell Carcinoma
Preetham Kumar Boominathan
Taiwan
EACR26-0884
P-675
TUMOUR EVOLUTION AND HETEROGENEITY
Single-Cell Resolution of Metabolic Adaptation to Glucose Deprivation in Ovarian Cancer PDXs
Eleonora Angi
Italy
EACR26-0952
P-676
TUMOUR EVOLUTION AND HETEROGENEITY
Fused Morphological and Genomic Analysis Reveals Early Chromosomal Mutational Burden in Normal Adjacent Colorectal Cancer Tissue
Marianna Kucarov
Hungary
EACR26-0966
P-677
TUMOUR EVOLUTION AND HETEROGENEITY
Population-Specific ecDNA Landscapes in Bladder Cancer: Divergent Oncogenic Drivers and Their Roles in Therapeutic Resistance
Boyeon Kim
South Korea
EACR26-1242
P-678
TUMOUR EVOLUTION AND HETEROGENEITY
Disentangling tissue heterogeneity in pancreatic cancer with spatial proteomics
Stella Koutsouli
Italy
EACR26-1318
P-679
TUMOUR EVOLUTION AND HETEROGENEITY
Laterality and the IVC thrombus signal in renal cell carcinoma with brain metastases
Seonhyeob Kim
South Korea
EACR26-1456
P-680
TUMOUR EVOLUTION AND HETEROGENEITY
Epithelial-to-Neuroendocrine Transition as a Therapy Resistance Mechanism in HER2-amplified Breast Cancer
Beatrice Charlotte Tröster*
Germany
EACR26-1550
P-681
TUMOUR EVOLUTION AND HETEROGENEITY
Assessment of tissue-level differences among MRI-defined habitats in Glioblastoma
Víctor Montosa Micó
Spain
EACR26-1592
P-682
TUMOUR EVOLUTION AND HETEROGENEITY
Mapping and modelling ADC targets in HGSOC
Sara Bystrup
Spain
EACR26-1668
P-683
TUMOUR EVOLUTION AND HETEROGENEITY
Investigating non-genetic drivers of intra-clonal competition in PDGF-driven glioma using a multiomic barcoding strategy
Sebastian Andres Garcia Mena
Italy
EACR26-1814
P-684
TUMOUR EVOLUTION AND HETEROGENEITY
Single-Cell Transcriptomic Analysis Reveals Heterogeneous Gene Expression Patterns in the Tumor Ecosystem of Laryngeal Squamous Cell Carcinoma
Marianna Scrima
Italy
EACR26-1842
P-685
TUMOUR IMMUNOLOGY
Stimuli-Responsive Nanozyme Reprograms Tumor Immunometabolism and Overcomes Therapeutic Resistance in Hepatocellular Carcinoma
Shen-Nien Wang
Taiwan
EACR26-0202
P-688
TUMOUR IMMUNOLOGY
Tumour-sensing stroma establish Treg-mediated immune suppression in metastatic ovarian cancer via GITRL-GITR signalling.
Julia Moreno-Vicente
United Kingdom
EACR26-0256
P-689
TUMOUR IMMUNOLOGY
Tumor-associated Mesenchymal stem cells (t-MSCs) suppress adaptive anti-tumor immunity in breast cancer
Zaid Shaikh
India
EACR26-0300
P-691
TUMOUR IMMUNOLOGY
Regulatory T cells sabotage anti-tumor γδ T cells by creating IL-2-deficient environments
Rafael Blanco-Domínguez
Portugal
EACR26-0330
P-692
TUMOUR IMMUNOLOGY
Investigating the Immunological Roles of Semaphorin 6A in Human Lung Cancer Cells
Jyh-Shiuan Hsu
Taiwan
EACR26-0350
P-693
TUMOUR IMMUNOLOGY
Diversity of myeloid cells in the tumor microenvironment highlights antigen presentation-related functional states
Natalia Ochocka
Poland
EACR26-0368
P-694
TUMOUR IMMUNOLOGY
Reprogramming the Tumor Immune Landscape: The Role of PLA2G12A
Eva Parisi
Spain
EACR26-0378
P-695
TUMOUR IMMUNOLOGY
Spatial in vivo CRISPR screen identifies metabolic regulators of the immune microenvironment in non-small cell lung cancer
Marina Leiwe
Australia
EACR26-0416
P-696
TUMOUR IMMUNOLOGY
Peripheral immunophenotyping reveals systemic immune activation in Lynch syndrome
István Kelemen
Hungary
EACR26-0450
P-697
TUMOUR IMMUNOLOGY
The Glucocorticoid Receptor Controls Anti-Tumor Immunity in KRAS-Driven Lung Adenocarcinoma
Herwig Peter Moll
Austria
EACR26-0458
P-698
TUMOUR IMMUNOLOGY
Differentiation-specific HLA class II expression sensitizes therapy-resistant melanoma to cytotoxic CD4 T cells
Simone Stupia
Germany
EACR26-0476
P-699
TUMOUR IMMUNOLOGY
Integrated Analysis of Circulating Microbial DNA and Cutaneous Lipid Profiling Define Early Diagnostic Signatures in Melanoma
Ayse Caner
Turkey
EACR26-0520
P-700
TUMOUR IMMUNOLOGY
Constitutive MHC-II expression through GLP (EHMT1) depletion: Opportunities for Antitumour Immunity in Colorectal Organoid
Nahla Elzefzafy
United Kingdom
EACR26-0526
P-701
TUMOUR IMMUNOLOGY
STING expression predicts sensitivity to STING agonists in ovarian cancer organoid models
Chloé Perichaud
France
EACR26-0532
P-702
TUMOUR IMMUNOLOGY
In Vivo CRISPR Screening Identifies Immune Checkpoint Associated Genes in Pancreatic Ductal Adenocarcinoma
Shuwen Zheng
Germany
EACR26-0544
P-703
TUMOUR IMMUNOLOGY
Radiotherapy promotes the recruitment and activation of intra-tumoural DCs and enhances CD64+CCR7+ cDC2 egress to the draining lymph node
Christopher Jones
United Kingdom
EACR26-0590
P-704
TUMOUR IMMUNOLOGY
SERPINA3 promotes tumor growth by suppressing CD8+ T cell activity
Hannes Linder
Denmark
EACR26-0602
P-705
TUMOUR IMMUNOLOGY
Complement-driven immune remodeling in brain metastasis
Rui Santalla Mendez
Switzerland
EACR26-0612
P-706
TUMOUR IMMUNOLOGY
A genomics-to-function pipeline reveals Des-like steroid metabolism shaping androgen pools in the microbiota–tumor axis
Giada Andrea Cassanmagnago
Switzerland
EACR26-0634
P-707
TUMOUR IMMUNOLOGY
Neutrophil extracellular traps derived from pancreatic ductal adenocarcinoma facilitate immune evasion through T-cell exhaustion and mitochondrial dysfunction
Sakshi Bansal
India
EACR26-0706
P-708
TUMOUR IMMUNOLOGY
Investigating the role of Bhlhe40 in dendritic cell metabolism and its impact on the tumor microenvironment
Christian Simini
Italy
EACR26-0726
P-709
TUMOUR IMMUNOLOGY
Primary breast tumour induces local and systemic alterations in circadian immune characteristics
Eva Hadadi
Belgium
EACR26-0748
P-710
TUMOUR IMMUNOLOGY
Platelets confer immunotherapy resistance via the reprogramming of myeloid cells to suppress effector T cell function in hepatocellular carcinoma
Shing Kam
Germany
EACR26-0756
P-711
TUMOUR IMMUNOLOGY
Integrated multi-omics analysis reveals tumor immune microenvironment in pediatric brain tumors
Minji Gwon
South Korea
EACR26-0800
P-712
TUMOUR IMMUNOLOGY
The potential immune modulatory role of MAP3K7 in hepatocellular carcinoma
Yee Lok Tsoi
Hong Kong, China
EACR26-0858
P-713
TUMOUR IMMUNOLOGY
Exploring the intra-tumoral microbiome of high grade serous ovarian carcinoma
Oussama Krami Senhaji
Morocco
EACR26-0960
P-714
TUMOUR IMMUNOLOGY
Dissecting the Prostate Cancer Microbiome to Understand Ethnic Disparities in Clinical Outcomes.
James Thetford
United Kingdom
EACR26-0996
P-715
TUMOUR IMMUNOLOGY
Immune Remodeling Driven by DGKζ Reflects Antitumor Activity in Bladder Cancer
Ane Ochoa Echeverría
Spain
EACR26-1090
P-716
TUMOUR IMMUNOLOGY
The immunological road to bone: the role of B cells in breast cancer bone metastasis
Ana Teijeiro
United States
EACR26-1114
P-717
TUMOUR IMMUNOLOGY
When immunity becomes a trap: NETosis in metastatic hormone-naïve prostate cancer
Jaione Auzmendi-Iriarte
Spain
EACR26-1116
P-718
TUMOUR IMMUNOLOGY
Zeb1-mediated immune evasion promotes colorectal cancer metastasis
Sevgi Ciraci
Germany
EACR26-1216
P-719
TUMOUR IMMUNOLOGY
Glioma Exosomes Mediate Systemic Immune Suppression Through Myeloid Cell Targeting
Emily Xu
United States
EACR26-1238
P-720
TUMOUR IMMUNOLOGY
Five dominant amino acid substitution signatures shape tumour immunity
Dóra Alexandra Gyémánt
Hungary
EACR26-1316
P-721
TUMOUR IMMUNOLOGY
Immune–ECM Crosstalk Defines an Immunosuppressed Microenvironment and Reveals Novel Therapeutic Targets in Desmoplastic Small Round Cell Tumor
Anastasiya Voronovska
Portugal
EACR26-1326
P-722
TUMOUR IMMUNOLOGY
NK cell-driven tumor immunoediting reveals LGALS3BP as a mediator of immune escape in leukemia
Eva M. Putz
Austria
EACR26-1384
P-723
TUMOUR IMMUNOLOGY
HuR inhibition modulates immune recognition of EGFR-mutant NSCLC cells
MARIA CASCIELLO
Italy
EACR26-1388
P-724
TUMOUR IMMUNOLOGY
Targeting myeloid compartment to enhance immunotherapy responses in Glioblastoma
Laura Carrillo-Bosch
Spain
EACR26-1394
P-725
TUMOUR IMMUNOLOGY
Balanced or imbalanced? The role of combined HLA-I - HLA-II recognition on antitumor immunity
Benjamin Papp
Hungary
EACR26-1434
P-726
TUMOUR IMMUNOLOGY
Tumor-Derived Exosomes Promote Peritoneal Metastasis in Ovarian Cancer via ICAM-2-Mediated Recruitment of Plasmacytoid Dendritic Cells
MACY YAN YI YUEN
Hong Kong, China
EACR26-1446
P-727
TUMOUR IMMUNOLOGY
Targeting PDAC immunosuppressive microenvironment: the therapeutic potential of the truncated O-glycan Sialyl-Tn
Inês Ribeiro
Portugal
EACR26-1452
P-728
TUMOUR IMMUNOLOGY
Cytokine-driven regulation of immune checkpoint expression in a model of tumour-associated macrophages
Anna Kusienicka
Austria
EACR26-1494
P-729
TUMOUR IMMUNOLOGY
Screening repurposed metabolic drugs to reactivate the anti-tumour immune response in gastroesophageal adenocarcinomas.
Kayla Brugman
Netherlands
EACR26-1496
P-730
TUMOUR IMMUNOLOGY
TrkAIII oncoprotein promotes PD-L1 expression of SH-SY5Y neuroblastoma cells via PI3K and beta-Catenin/TCF
Maddalena Sbaffone
Italy
EACR26-1508
P-731
TUMOUR IMMUNOLOGY
TLR2 as a potential therapeutic target to improve chemotherapy efficacy in osteosarcoma
Flavia D'Achille
Italy
EACR26-1540
P-732
TUMOUR IMMUNOLOGY
Hormonal and oncogenic crosstalk contributes to the regulation of glyco-immune checkpoints in prostate cancer
Adam Duxfield
United Kingdom
EACR26-1604
P-733
TUMOUR IMMUNOLOGY
The role of Akkermansia muciniphila in the prevention and chemo-immunotherapy of H. pylori-associated gastric tumors
Francesca Bruzzese
Italy
EACR26-1616
P-734
TUMOUR IMMUNOLOGY
Immune microenvironment reprogramming drives malignant progression in PDGF-driven gliomas
Paolo Malatesta
Italy
EACR26-1670
P-735
TUMOUR IMMUNOLOGY
Melanoma immune phenotyping by bulk RNA-seq identifies inflamed, excluded and desert tumour ecosystems
Egle Zymantaite
Lithuania
EACR26-1700
P-736
TUMOUR IMMUNOLOGY
Opportunity and limits of immunotherapy in Notch-dependent T-cell acute lymphoblastic leukemia
Noemi Martina Cantale Aeo
Italy
EACR26-1722
P-737
TUMOUR IMMUNOLOGY
Characterization of fresh patient biopsies using secretome and immune analysis reveals cancer cell derived myeloid chemoattractants as a central feature of T cell excluded gastroesophageal adenocarcinomas
Jasper Sanders
Netherlands
EACR26-1754
P-738
TUMOUR IMMUNOLOGY
FKBP5 Splicing Governs Lymphocyte Exhaustion and Tumor Immune Tolerance
Laura Marrone
Italy
EACR26-1760
P-739
TUMOUR IMMUNOLOGY
MEDITERRANEAN DIET BIOACTIVE COMPONENTS AND INHIBITION OF ELONGATION FACTOR 2 (EF2) REPROGRAM TUMOR AND IMMUNE PATHWAYS IN SQUAMOUS CELL CARCINOMA
Sandro Arguelles
Spain
EACR26-1764
P-740
TUMOUR IMMUNOLOGY
Restoring epigenetically silenced cGAS-STING signaling to counteract immune evasion in Neuroblastoma
Roberto Schirano
Italy
EACR26-1862
P-741
TUMOUR IMMUNOLOGY
The spatial immune architecture of esophageal adenocarcinoma predicts response to neoadjuvant chemotherapy
Giuseppina Arbore
Italy
EACR26-2002
P-742
